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ABSTRACT 
 
HAO ZHU: Outcomes of China Free Antiretroviral Treatment Program, 2003 - 2010  
(Under the direction of Sonia Napravnik) 
 
Mortality and morbidity from HIV has dramatically decreased in both high- and low-
income countries. However, some patients may not benefit from combination antiretroviral 
therapy (cART) because of inadequate access to HIV care, including attrition after care 
initiation. Moreover, prior work has concentrated on internal comparisons of mortality 
among HIV-infected patients over time.  
This study had two specific aims. For the first aim, we described cumulative 
incidence rates of attrition and identified independent factors predictive of attrition. For the 
second aim, we evaluated observed mortality rates, excess mortality rates and standardized 
mortality ratios across calendar years. Factors associated with excess mortality across 
calendar time were evaluated in Poisson regression models. 
For the first aim, we observed a cumulative probability of attrition from cART 
initiation of 9% at 12 months, 16% at 24 months and 24% at 60 months. Factors were 
associated with attrition, including younger age, male gender, and being single or divorced. 
Patients with higher CD4 cell counts were more likely to drop out. The proportion of patients 
remaining in HIV care increased in more recent calendar years and among patients who 
initiated modern cART regimens. 
For the second aim, we found observed and excess mortality rates in 2003/2004 of 9.5 
deaths/100 person-years and 9.1; and in 2008/2009 these decreased to 5.6 and 5.2 
respectively. The adjusted excess hazard ratio (eHR) for 2003/2004 in comparison to 
iv 
2008/2009 was 1.27 (95% confidence interval [95% CI]: 1.11, 1.45). Patients initiating 
cART at CD4 cell counts <50 cells/μL in comparison to ≥350 cells/μL had an adjusted eHR 
of 9.92 (95% CI: 8.59, 11.44). Standardized mortality ratio results were consistent with those 
for excess mortality. 
In summary, attrition can lead to premature morbidity and mortality, and possibly 
affect further transmission of HIV and HIV resistant drug variants. In China effective 
strategies may include focusing particularly on younger male patients and those with higher 
CD4 cell counts at therapy initiation. Moreover, notable substantial decreases in excess 
mortality were observed from 2003 to 2009 in China among HIV-infected patients receiving 
free cART. However, mortality among HIV-infected patients remained higher than the 
general Chinese population.  
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I. SPECIFIC AIMS 
Specific Aim 1: To describe and evaluate attrition following combination 
antiretroviral therapy initiation in China, 2003-2010. 
Aim1a: To identify independent risk factors associated with time from cART 
initiation to attrition. Hypothesis: Patients who are younger, male, injecting drug users, 
receive HIV care at smaller clinics, reside in the western region of China, with lower CD4 
cell counts, earlier calendar year of starting cART, fewer symptoms and cART not including 
lamivudine will be at greater risk of attrition. 
Aim1b: To evaluate the effect of calendar year of starting cART on time to attrition. 
Hypothesis: Patients who initiated cART in earlier calendar years will be at greater risk of 
attrition after adjustment for demographic and clinical characteristics. 
Aim 1c: To evaluate the effect of type of health care setting on time to attrition. 
Hypothesis: Patients who initiated cART in central hospitals will be at lower risk of attrition.  
 
Specific Aim 2: To describe and evaluate excess mortality among HIV-infected 
patients receiving cART in comparison to the general population in China, 2003-2009. 
Hypothesis: Patients who are younger, male, injecting drug users, receive HIV care at smaller 
clinics, reside in the western region of China, with lower CD4 cell counts, earlier calendar 
year of starting cART, fewer symptoms and cART not including lamivudine will be at 
greater risk of excess mortality.  
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II. BACKGROUND 
The HIV Epidemic in China  
Based on the Chinese Notifiable Cases System, as of the end of October 2007, the 
cumulative number of HIV-infected persons diagnosed in China was 223,501, of whom 
62,838 had an AIDS diagnosis, as of the end of October 2007 [1]. Meanwhile, the official 
estimation of HIV-infected persons living in China was 700,000 with 20,000 AIDS related 
deaths observed through the end of 2007 [1]. The major route of transmission has been 
injection drug use (IDU), which accounts for 39% of infections, followed by former blood 
donation (19%), heterosexual transmission (18%), receipt of blood products (4%), mother to 
child transmission (1%) and homosexual transmission (1%). In the rest (18%) the 
transmission mode is unknown. The proportion of HIV-infected individuals in China who are 
male is more than twice that of female (71% vs. 29%) [1]. Figure 2.1 illustrates the 
geographical distribution of HIV accumulative cases in China through the end of 2009. 
HIV infection has rapidly grown in China since 1985 when the first case was reported 
in a foreign tourist. During 1985 to 1989, several cases were reported among patients 
infected by blood products or aboard [2]. The first indigenous HIV positive patients were 
reported in 1989 when one outbreak of HIV was found among heroin users in Yunan 
province, located in the southwest of China near the Golden Triangle border area between 
China and Myanmar [3-8]. Subsequently, HIV has been identified in the neighboring 
provinces of Yunan, including Guangxi, Sichuan, Guangdong, along with the drug 
trafficking routes. During the mid-1990s, HIV positive patients were recognized among 
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commercial plasma donors, which represented the second outbreak in central provinces of 
China. As of 1998, all 31 Chinese provinces had reported HIV-infected cases. From 1995 
through 2000, the reported number of new HIV cases rose by 30% each year; however, the 
rate of new diagnoses reached 58% in 2001 because of increased reporting of HIV-infected 
individuals infected through former blood/plasma donation and continued to rise with the rate 
reaching 122% in 2003 [3, 4]. 
According to results from the national sentinel surveillance, the average prevalence of 
HIV is currently 5% among IDUs living in China, with some blips as high as 50% to 80% in 
several provinces[3]. The infection rate among blood and blood product recipients was 9% in 
Henan province in 2004 and similar results were observed in other provinces [2]. Due to 
ongoing screening of blood and blood products this route of infection is decreasing in China. 
The estimated prevalence of HIV infection among China’s population is 0.05 % 
(range 0.04 - 0.07%) [1]. However, based on national sentinel site information, the 
prevalence of HIV infection among 81 national sentinel sites of STD patients has risen from 
26% to 46% between 2003 and 2006 [2]. During the same period, the prevalence of HIV 
increased from 33% to 44% among 36 national sentinel site of sex workers [2]. Among men 
who have sex with men (MSM) the prevalence is low, the impact cannot be negligible though 
[9]. 
In summary, in China the HIV epidemic continues to grow at a rapid pace, although 
certain regions and populations are affected more than others. 
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Chinese national HIV/AIDS surveillance system 
The China HIV/AIDS surveillance system developed in three phases [10-12]. In the 
first phase (before 1995), only passive reported surveillance existed. Cases from local 
hospitals and centers for diseases control at the county level were reported to provincial and 
central authorities. Two target populations were specially monitored: foreigners and female 
sex workers. Few active surveillance activities existed during this first phase except in 
selected provinces where HIV cases were being reported early. During the second phase 
(1995-1997), active surveillance was initiated through the HIV/AIDS sentinel surveillance 
system. This sentinel surveillance system included 42 national HIV sites in 23 provinces 
specifically focusing on several high risk populations. The third phase (1998-present) added 
behavioral surveillance surveys (BSS) into the national surveillance system. The BSS applied 
epidemiology and demography methods to conduct surveys among specific target 
populations to help project the Chinese HIV epidemic [10-12]. 
Currently, the Chinese surveillance program is an integrated single comprehensive 
system which includes the National HIV/AIDS case report system, the National HIV sentinel 
surveillance system, the National HIV behavioral surveillance system, and some additional 
specific surveys. The National Center for AIDS/STD Control and Prevention (NCAIDS) has 
been in charge of the national HIV surveillance system since 2001. To improve the quality 
and timeliness of HIV data, NCAIDS updated the surveillance system into a web based 
HIV/AIDS case reporting system, by which the NCAIDS can monitor the HIV/AIDS 
epidemic even at the daily county level [12]. 
The central government announced the China Comprehensive AIDS Response 
program in 2002, which integrated HIV care and treatment and prevention activities. Under 
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this initiative the National Free Antiretroviral Treatment Program (NFATP) was established 
and was integrated with the national HIV surveillance system. This new system enrolled 
HIV-infected patients, initiated them on combination antiretroviral therapy (cART) as 
indicated, and longitudinally followed patients - frequently in the first three months 
following cART initiation and then every three months, thereafter. This new system applied 
the same national identification code as used in the National HIV/AIDS case reported system 
allowing for linkages between the two systems. 
 
Attrition 
Attrition among HIV-infected patients after cART initiation. 
It has been well documented that cART suppresses HIV viral replication, lengthens 
patient’s survival and lowers AIDS-related mortality and morbidity in both a number of 
clinical trials and observational studies since its introduction in 1996 [13-19]. However, the 
discontinuation of cART, either due to attrition or suboptimal cART adherence, leads to 
failure of HIV RNA viral suppression, reversal of immune reconstitution [20-23] and 
potentially greater infectiousness. Therefore, the issue of attrition and the factors associated 
with attrition have been studied as described below. 
Definitions of Attrition: A number of studies describing and evaluating factors 
associated with attrition after initiation of ART are listed in Table 2.1. Studies adopted a 
range of time intervals as the definitions for attrition according to the study population, the 
study design and the accessibility of data. Normally, the definition of attrition could be 
classified into two categories: one definition of attrition consisted of traced deaths, transfers 
out to other facilities and untraced contacts (unknown contact) [24], whereas the other 
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definition included the non-death attrition or untraced contact only [25]. In addition, the 
definition of attrition applied different time intervals to classify the attrition among the 
patients. Table 2.1 shows a range of time intervals from more than 6 weeks [26] to the 
maximum, more than one year, to define the patients as lost to follow-up [27]. The definition 
with longer interval for attrition allows patients greater opportunity to come back to HIV care. 
Therefore specificity is likely higher in studies using a longer time interval to define attrition. 
However, sensitivity could be lower when longer intervals of time are used to define attrition. 
Therefore, due to differences in the definition and measurement of attrition across different 
studies results need to be interpreted cautiously particularly when comparing one study to 
another. Most studies done in both developing and developed income countries have 
evaluated the status and impact of attrition by actively tracking patients using their contact 
information such as mailing address or telephone after being identified as lost to care. In 
contrast, other studies in developing income countries have identified and evaluated attrition 
by cross-checking with vital registry records [28]. 
Prevalence of attrition: The prevalence of attrition is heterogeneous from different 
regions and populations, in part due to the different definitions of attrition used, study 
designs and analyses, and available sample sizes [29]. In Africa, for example, a systematic 
review mentioned the proportion of attrition ranged from 20% at 6 months to 40% at 2 years 
[29]. In addition, the study from Antiretroviral Therapy in Lower-Income Countries (ART-
LINC) collaboration reported an overall rate of attrition of 15% during the first year of ART - 
lower (12%) in settings with active follow up and higher (19%) in settings with no or passive 
follow up [18]. In summary, across studies, the proportion of attrition after ART initiation 
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ranged from 2.6% for two years to 32% for three years follow up in low-income countries 
during studies conducted between 1992 and 2006 (Table 2.1) [30-36]. 
In contrast, the proportion of attrition was generally lower in developed countries 
than among developing countries. For example, in one randomized clinical trial in the USA, 
the percent of attrition was 3% after the first year follow-up in 1988 and the cumulative 
proportion of attrition was 34% in 1994 after seven years of follow-up [30]. Further, the 
probability of attrition based on French cohort data was 3% during 6 months follow up [27, 
37, 38]. Overall, these numbers were dependent on the study population, study period and 
definitions used. 
Factors related to attrition: Factors associated with attrition among HIV-infected 
patients receiving cART have been assessed in previous studies and showed differing 
conclusions. In developing countries, one of the most important reasons for attrition was 
socioeconomic factors. For instance, Maskew et al reported that the most frequent reason for 
attrition in a South African cohort was financial concerns [39]. Also, Zachariah et al showed 
that patients who had to pay for cART were more likely to be lost to care among patients 
receiving cART in Kenya [40]. Demographic characteristics including age, race and 
education have been examined for their association with attrition. The majority of studies 
conducted in developing settings did not find associations between attrition and demographic 
factors [33, 40-44]. Gender has been associated with attrition in some studies [25, 27, 44] but 
not all [43] with men both more and less likely to be lost to care in comparison to women. 
Additionally, most studies in developing countries have also not observed differences in 
attrition based on the patient’s clinical status including CD4 cell count, HIV RNA viral load, 
the presence of a clinical AIDS diagnosis, or weight [24-26, 28, 31-33, 40-46]. 
 8 
On the other hand, in developed areas of the world demographic factors including 
younger age, male gender, black race and IDU have been reported to be associated with 
attrition. The potential explanation for the discordant findings in comparison with developing 
countries could be due to more power with larger sample sizes, more detailed and precise 
measurements of study variables, in addition to differences in study populations and care 
provision practices. Like findings from developing areas, patient clinical factors including 
CD4 cell count and HIV RNA level did not appear to be associated with attrition in the 
majority of studies that evaluated these factors in developed areas [27, 30, 34-38, 47, 48]. 
 
Effects of attrition among HIV-infected patients initiating cART 
How attrition can affect research studies: Attrition, if substantially large enough, can 
affect results of both randomized clinical trials and observational clinical studies and its 
effects need to be minimized through both improved study designs and advanced statistical 
methods [30, 35]. Attrition can bias the validity of analyses among patients initiating cART 
by introducing a selection bias and decreasing statistical power [49]. Attrition may affect 
analyses if patients who are lost are not a random sample of patients from the entire study 
population and, therefore, may have greater or lesser probability of experiencing the event of 
interest, introducing informative censoring [49]. 
Patients lost to follow up may be sicker than the rest of the cohort and therefore more 
likely to die [37]. Studies assessing the impact of attrition on results showed that these 
analyses may underestimate the risk of mortality due to partial death ascertainment among 
patients who are lost to HIV care. For example, Macphers and Lawn [26, 27] showed that 
over 50% of the patients lost to care in a rural South African cohort were deceased. The 
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ART-LINC study investigators contrasting mortality between developed and developing 
countries observed a higher rate of attrition in low income settings possibly underestimating 
the mortality rates in these settings [18].  
How attrition can affect clinical care outcomes: In addition to its methodological 
impact, attrition can also affect HIV clinical care outcomes. Attrition generally and 
particularly in China means that patients will also discontinue their cART, placing them at 
higher risk of AIDS and non-AIDS clinical conditions and mortality. The cessation of cART 
not only affects an individual patient’s health, it can also have a detrimental impact on the 
ongoing HIV epidemic through increased transmission. Specifically, successful cART leads 
to lower genital tract HIV RNA levels and hence a lower likelihood of HIV transmission [50]. 
Additionally once a patient is no longer engaged in HIV care, additional secondary 
prevention, including discussions about transmission prevention are no longer possible. 
Therefore evaluating attrition, its associated factors, and implementing means to reduce 
attrition is important for both individual and public health. 
Strengths and weaknesses of prior studies: 
Many of the prior studies have had a number of strengths. The majority of studies in 
developing areas and most of the studies in developed areas had larger sample sizes and had 
observational periods of follow up that were more than one year. Therefore, these studies 
with sufficient sample size coupled with longer follow-up period yield a proportion of 
patients with attrition that then provides opportunities to examine potential risk factors for 
attrition in order to make effective policies and intervention methods. Studies conducted in 
the developed countries included even more participants than those in developing countries. 
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In previous studies, a significant proportion of patients lost to care died. Yu et al, [24] 
reported 50% of patients lost to HIV care were dead and 27% were untraceable. Of the 
studies listed in Table 2.1, a traced mechanism or active follow up was used in most studies 
in resource-limited setting and in all studies in developed countries. Using an active tracking 
system in cases of loss to HIV care can supply details regarding patient outcomes and further 
identify any risk factors associated with greater risk of loss to care. Also, active tracking 
mechanisms allow researchers to correct survival analysis estimates with data to account for 
potential biases arising from differential loss to follow-up [46]. 
Prior studies of attrition also encountered a number of limitations. First, the 
generalizability of these studies should be interpreted carefully. Differences in the data 
sources, the study settings and the definition of attrition applied could lead to heterogeneity 
of the enrolled subjects even in same country. The studies observed in South Africa, for 
example, have different conclusions about attrition even though they used the same data 
sources. Cornell et al used more than 3 months as a cut point for attrition while Lawn et al 
applied more than 4 weeks. As a result, the proportion of attrition in each study was not 
similar [26, 41].  
Second, the time trend effect of attrition may not be well established although studies 
included adequate sample size. Regardless of whether the studies were carried out in 
developing or in developed countries, most have followed patients approximately one year 
after enrollment. One exception is a clinic trial conducted by Ioannidis et al [30]. They 
followed up 1,609 patients since 1997 until 2004 and found the proportion of attrition ranged 
from 3% to 34% during seven years follow up. 
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Third, the potential risk factors evaluated in prior studies were varied. Generally, the 
demographic factors such as age, gender and race and the health status of patients such as 
baseline CD4 cell count, HIV viral load and AIDS status were assessed not only in 
developing but in developed countries. In contrast, few studies from low income countries 
have evaluated immigrant issues and social economic factors. However, studies conducted in 
France found that immigrant status, employment status, homelessness and accessibility of 
medical care could also impact the retention of patients [27, 37]. Therefore, because the risk 
factors associated with attrition were examined differently, conclusions conflicted among 
studies. Further study is necessary to identify factors for attrition. 
Lastly, another limitation is the potential for information bias. Prior studies acquired 
information about the patients mainly through medical records, which may not supply precise 
or current information. Therefore, the results from prior studies may be biased due to 
misclassification [27]. 
In summary, the proposed study (n=67,732) will improve on prior work in a number 
of ways. Foremost, this study will use a very large national and representative cohort to 
evaluate attrition, and importantly will be able to rely on up to seven years of follow-up. 
Additionally, we will be able to evaluate a number of factors that may be independently 
associated with attrition, including sociodemographic factors including: age, gender, mode of 
HIV transmission, and geographic residence; as well as clinical factors including: type of 
HIV care provider, CD4 cell count and baseline symptoms. This information will be 
important to assessing attrition in the free cART program in China and informing the 
development of interventions to improve both individual and public health. 
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Mortality among HIV-infected patients initiating cART 
Crude mortality among HIV-infected patients initiating cART 
With the introduction of cART, the rates of mortality and morbidity among HIV-
infected patients sharply decreased [17-19], although the survival benefits have been 
disproportionate between developing and developed countries. According to one study 
conducted in 18 low-income programs by ART-LINC, the mortality at 1 year following ART 
initiation was estimated at 6.4% [95% confidence interval (CI): 5.1, 7.7] with active follow 
and 2.3% (95% CI: 1.5, 3.2) with passive follow up [18]. Also, a review of 18 published 
studies in sub-Saharan Africa between 2002 and 2008 reported mortality rates at 1 year from 
cART initiation of 8% to 26% [51]. Studies from Latin American and south-east Asia 
identified mortality rates at one year after starting therapy of 8.3% and 11%, respectively [28, 
52]. A study by Zhang et al reported high mortality rates during the first 3 months following  
cART initiation (22.6 deaths per 100 person-years) and decreasing thereafter among HIV-
infected patients initiating cART in China [53].  
In industrialized countries, on the other hand, observed morality rates have been 
lower. The estimated mortality from 12 cohort studies by Antiretroviral Cohort Collaboration 
(ART-CC) during 1 year was 1.8% (95% CI: 1.5, 2.2) [18]. Also, the crude all-cause death 
rate reported by ART-CC was 12.1 deaths per 1000 person-years (95% CI: 11.6, 12.7) during 
1996 to 2006.  Moreover, one analysis based on data from 18 cohorts across Europe and 5 
cohorts from North America between 1990 and 2004 reported an overall mortality of 5.2 per 
1000 person-years (95% CI: 4.7, 5.7) [54]. Overall, mortality rates in ART programs are 
higher in developing countries than in developed countries, but are heterogeneous with 
generally much higher rates in sub-Saharan Africa compared with other regions [51]. 
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Calendar time trends in mortality among cART treated HIV-infected patients 
Essentially all studies carried out either in developing or developed countries have 
observed decreased morbidity and mortality in more recent calendar intervals (Table 2.2), 
although some issues including the accessibility of potent cART [55-59], difficulties with 
long-term adherence [60-66] and toxicity or drug resistance [67-71] have impacted the 
effectiveness of cART, regardless of setting. For instance, a study conducted in Canada 
found mortality rates decreased from 11.7/100 person-years in calendar years 1984-1996 to 
2.4/100 person-years in years 1997-2003 [72]. Similarly, Palella et al documented a drop in 
mortality rates from 3.79/100 person-years in 1996 to 0.32/100 person-years in 2004 using 
data from the US [73]. A number of other studies have observed similar findings [73-75] and 
have also consistently documented longer times to AIDS events and greater survival periods 
following ART initiation in more recent calendar years [14, 76-84]. 
 
Risk factors associated with mortality among cART initiated HIV-infected patients 
Risk factors associated with increased mortality following cART initiation are 
summarized in Table 2.3. In industrial countries, almost all of previous studies found an 
association between CD4 cell count measured at cART initiation and an increased risk of 
morbidity and mortality when cART was initiated at lower CD4 cell counts [28, 32, 85-101]. 
In Europe, one analysis carried out among 14,208 subjects from 15 cohorts, part of the ART-
CC, found CD4 cell count to be an important prognostic factor for death among HIV-infected 
patients [102]. Further evidence of a relationship between baseline CD4 cell count and 
mortality was provided by two other publications. In one analysis including 15 cohort studies 
from ART-CC [103], the authors reported patients who initiated cART at CD4 cell count 
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between 251-350 cell/ul had higher rates of AIDS and death than those who began cART at 
CD4 cell counts between 351-450 cell/ul (HR 1.28, 95% CI 1.04-1.57). Kitahata et al. also 
observed improved clinical outcomes when patients initiated cART at higher CD4 cell counts 
[104]. Similarly, the North American AIDS Cohort Collaboration on Research and Design 
(NA-ACCORD) also found an association between CD4 cell count and mortality among 
patients who received therapy and experienced a virologic failure [105]. Thus, results from 
studies highlight the association between the CD4 cell count and mortality among HIV-
infected patients. 
In addition to CD4 cell count, other potential factors for mortality have also been 
evaluated. For instance, using data from NA-ACCORD, Deeks found that higher HIV RNA 
levels were associated with a higher relative hazard for mortality compared with that of HIV 
RNA level less than 10,000 copies/ml after second virologic failure [105]. Similar results of 
the association between HIV RNA level and mortality were found by other previous studies 
[102, 106]. Moreover, patients who were infected via injection drug use have been generally 
observed to be at greater risk of mortality [32, 101, 107-110]. Lower body mass index (BMI) 
or body weight are more likely to decrease survival time compared with higher baseline BMI 
or body weight [28, 85, 86, 88, 90, 93, 99, 100]. Advanced age is another risk factor 
documented by several large-size, prospective cohort studies to be associated with an 
increased risk of mortality [97, 100]. Other studies have found conflicting results for 
independent effects on mortality of other demographic factors including gender and race [28, 
32, 85-101, 107, 109, 110]. 
The important protective effect of initiating cART at higher CD4 cell counts has also 
been observed in resource poor regions of the world. For example, a cohort study was 
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conducted among 2423 patients receiving ART for up to five years in South Africa by Lawn 
et al [97]. They found patients with the baseline CD4 cell counts less than 100 cells/ml were 
more likely to die compared with those patients with the baseline CD4 cell counts at least 
100 cells /ml. In this study older age was also associated with a higher risk of mortality, but 
gender/sex did not seem to affect mortality risk. Another analysis in sub-Saharan Africa 
using data collected through the International epidemiologic Databases to Evaluate AIDS 
(IeDEA) project conducted by May et al from 2004 to 2007 observed similar results.[100] 
specifically, among 11,153 patients who started ART, longer survival was strongly 
associated with higher baseline CD4 cell count (adjusted hazard ratio 0.21; 95% CI: 0.17, 
0.27 for ≥200 cell/ul). Higher mortality was also statistically associated with lower body 
weight, older age and lower lymphocyte count. However, male gender in this study was 
associated with greater mortality. Lawn et al reported that patients with HIV RNA levels of 
more than 400 copies/ml after cART imitation were more likely to die (relative risk 2.06; 95% 
CI: 1.37, 3.09) [97]. May et al reported patients with advanced clinic stage were 2.96 times 
more likely to die than patients without advanced disease [100]. 
In brief, patients who are older, have lower CD4 counts, higher HIV RNA levels, 
advanced clinical stage, lower body weight, and lower lymphocyte count have been observed 
to be consistently at greater risk of mortality. However patients’ race and gender do not seem 
to be consistently associated with mortality. 
 
Excess mortality of HIV-infected patients who initiated cART 
An alternative to evaluating mortality among HIV-infected individuals is to assess 
mortality among HIV-infected individuals in comparison to HIV-uninfected individuals. 
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Although a prospective cohort study including both HIV-infected and uninfected individuals 
would be ideal, it is possible to use readily available mortality rate data that is stratified by 
sex, age group and calendar year to compare the expected mortality to that which is observed. 
The observed mortality consists of expected and excess mortality (e.g. the mortality related 
to HIV-infection) [111]. Two possibilities for estimating excess mortality include the excess 
mortality rate (absolute scale) and standardized mortality ratio (SMR) (relative scale). The 
excess mortality is the difference between the mortality of HIV-infected patients who 
initiated cART and the mortality in general population matched for age group, sex and 
calendar year. The SMR is ratio of observed survival to the expected survival generated from 
the national general population after adjusting age, sex and calendar year to study population. 
Advantages of this approach include, an estimate of excess mortality due to HIV-infection 
(biologic factors as well as contextual factors) in comparison to the mortality observed in the 
general population, and thus, do not need the information for individual’s cause death. It is 
important to match on age group and sex in these analyses [112]. 
Excess mortality analyses using data on population mortality rates have been used 
extensively in cancer studies for several years [113]. In HIV a number of studies have 
evaluated excess mortality in Europe and Africa. One study has been conducted by 
Bhaskaran et al by using data from the Concerted Action on Seroconversion to AIDS and 
Death in Europe [114]. They found excess mortality decreased from 41/1000 person-years 
before 1996 to 6/1000 person-years in 2004-2006 and concluded the mortality rates for HIV-
infected patients have become closer to mortality in general population after introduction of 
cART [114]. This study is important because it includes information on timing of HIV-
infection in addition to timing of cART initiation. Brinkof has also showed that the mortality 
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of HIV-infected patients who initiated cART were still higher compared with that in general 
population in Sub-Saharan African, although excess mortality in some patient groups was 
improving in comparison to the general population [115]. Keiser and Jaggy also evaluated 
excess mortality among HIV-infected patients in comparison to the general Swiss population 
[116, 117]. 
In summary, notwithstanding modern cART, HIV-infected individuals continue to 
experience excess mortality in comparison to the general population even among individuals 
who successfully respond to cART [118, 119]. Using excess mortality analyses is critical to 
provide policy makers with accurate information to evaluate the effect of cART and monitor 
the change of mortality among HIV-infected patients at a general population level. 
 
Decentralization of cART among HIV-infected patients 
In resource rich areas of the world, the majority of patients with HIV-infection are 
followed by clinicians with specialized HIV treatment knowledge and with access to 
relatively sophisticated and expensive laboratory and other types of monitoring [120]. 
However this level of HIV care is difficult to provide in resource poor areas of the world 
because of scarce resource and lack of HIV experienced clinicians. On the other hand, the 
majority of people infected with HIV live in developing countries. Therefore, WHO has 
strongly supported cART provision even in the most resource deprived areas of the world 
[121]. Previous studies have evaluated how best to provide HIV care and ART in developing 
countries. One study which included 5719 HIV-infected patients in South Africa evaluated a 
decentralized model of cART provision in rural areas [122]. The study found that the overall 
mortality rate was high but was similar to mortality rates observed in more urban areas and in 
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more specialized programs also in South Africa. Notably, the rate of attrition was relatively 
lower in this rural study population in comparison to urban areas. Other studies also 
conducted in South Africa have observed similar success in delivery of HIV care and cART 
in rural and impoverished areas [123]. As prior studies showed, attrition was lower in these 
rural clinics than in hospital based HIV clinics [123]. Comparable results have also been 
reported from neighborhood countries [124, 125]. 
In summary although HIV care and cART provision can and are successfully 
provided throughout resource limited settings additional work is needed to identify program 
structures that lead to the best patient clinical outcomes.  
 
Strengths and weaknesses of prior studies: 
A large number of studies have evaluated mortality among HIV-infected individuals 
receiving cART across many calendar years, areas of the world, and program settings, with 
many of these studies of exceptionally high quality. Many prior studies have had large 
sample sizes leading to more power and precision. Some studies in Table 2.2 had more than 
1,000 subjects and some had more than 10,000 subjects. These relatively large sample sizes 
have allowed investigators to evaluate mortality in specific subgroups of patients and across 
calendar time. Also the wide distribution of studies globally has allowed investigators to 
draw conclusions that are often generalizable to many HIV-infected individuals receiving 
HIV care and cART around the globe. 
On the other hand, some prior studies have also had certain limitations. First, several 
studies lacked information on potential confounders and therefore they were not able to 
completely exclude the possibility that some of their findings may be due to unmeasured 
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confounding. For example, Schewarcz et al acknowledged that their study could not adjust 
for HIV RNA levels or systemic symptoms, which may impact patients’ survival time [79]. 
Also, Nash et al mentioned they did not add specific factors including health insurance, 
access to treatment and health behavior factors into their analysis [83]. Secondly, in some 
cases studies were affected by high mortality rates among patients who were lost to HIV care. 
As mentioned by Couzgou [80], 12% of their study patients who were lost to care were 
younger, infected by heterosexual activity and diagnosed with tuberculosis, all factors related 
to shorter survival time in this cohort. These authors also noted that their findings may be 
affected by survival bias since only patients who survived long enough to initiate cART were 
included in their study (as is common among many studies evaluating HIV related mortality) 
[80]. 
The present study builds on prior work in a number of ways. First this is one of the 
largest cohorts of HIV-infected individuals internationally, and the only one of its size and 
scope in China. To date no analyses have focused specifically on retention and attrition 
among the large number of HIV-infected individuals receiving free cART through NFATP. 
Understanding who becomes lost to HIV care and the scope of this problem in China is 
important to intervene to improve both individual and public health in a country where HIV 
infection continues to spread rapidly. Additionally evaluating mortality among HIV-infected 
patients receiving cART in China across calendar years and in comparison to the general 
Chinese population will provide important data for policy makers.  
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Table 2.1 Rates of attrition and risk factors among HIV-infected patients initiating cART 
 
First Author Year Region N Definition of 
attrition 
Active 
Follow 
up 
Ratio/Rate Risk factors for attrition 
Geng [46] 2009 Ugand
a 
3,628 6-month absent from 
clinic 
Yes 22%  during  
3.5 yrs 
N/A 
Cornell [41] 2009 South 
Africa 
2,196 Patients who have 
start ART but were 
absent more than 
3months 
N/A 6%  during 
1yr 
1)Lower incoming was associated with 
attrition;  
2)Age, gender, baseline CD4, VL not 
associated;  
3)Not others were tested 
Macpherson 
[25] 
2008 South 
Africa 
1,353 Patients who could 
not be traced and not 
returned to clinic 
during 24 months. 
(Non-death attrition) 
Yes 2.6%  during  
2yrs 
1)male, lower weight,  lower baseline CD4, 
WHO stage 3-4 were associated with attrition 
2) Not others were tested 
Kaplan[42] 2008 South 
Africa 
1,677 Patients with ART 
who not attended the 
clinic >12 weeks 
No 32% during  
3 yrs 
 
1)Pregnancy, young age were associated with 
attrition 
2) WHO stage, baseline CD4, VL not 
associated; 
3)Not others were tested 
Dalal  [45] 2008 South 
Africa 
1,631 Receiving ART and 
disappear > 6weeks 
Yes 16.4%  
during 1yr 
N/A 
Lawn [26] 2006 South 
Africa 
927 Receiving ART who 
were>4 weeks late 
for scheduled clinic 
visit 
Yes 11.9% during  
3yrs 
1) baseline CD4 were not associated with 
attrition 
2) Not others were tested 
Yu [24] 2007 Malawi 5,009 Patients who have not 
seen in clinic for 3 
consecutive months 
Yes 5.1% N/A 
Fetzer [126] 2009 Malawi 258  N/A No 12% N/A 
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Table 2.1 Rates of attrition and risk factors among HIV-infected patients initiating cART (continued) 
 
First Author Year Region N Definition of 
attrition 
Active 
Follow 
up 
Ratio/Rate Risk factors for attrition 
Zachariah [40] 2007 Kenya 435 Receiving ART and 
disappear >2 months 
No 47.2 and 20.5 
per 100pys 
for payment 
and free 
cohort 
1)Payment for ART was associated with 
attrition 
2) Gender, age, Marital status and baseline 
CD4 were not associated 
3) Not others were tested 
Karcher [43] 2007 Kenya 159 Receiving ART and 
disappear within 4 
months after a 
scheduled 
appointment 
Yes 43.2 per 
100pys 
1) Adherence<2m was associated with 
attrition 
2) Age, gender, race, education, baseline 
CD4, pregnancy were not associated with 
attrition. 
3) Not others were tested 
Lowrance [44] 2009 Rwanda 3,194 Patients who have not 
been seen at the clinic 
for any reason for 
>90 days 
No 3.1% at 
6M;4.9% at 
12M 
1)Man, lower Baseline CD4 and lower body 
weight were associated with attrition;  
2)Age not associated with attrition; 
3) No other factors were tested 
Toure [33] 2008 West 
Africa 
10,21
1 
Last contact with 
program>3 months  
or >6months  while 
do not know to be 
dead or transferred 
out 
No Prob. 0.21 in 
18 months 
1)man, experienced clinical, low hemoglobin 
were associated with attrition; 
2)Age, baseline CD4 counts  were not 
associated with attrition; 
3) No other factors were tested 
Nacher [31] 2006 French 
Guiana 
1,213 Permanent 
interruption 
No 17.2 per 100 
pys 
1)age<40 and lower baseline CD4  were 
associated with attrition; 
2) gender and baseline CD4 were not 
associated with attrition 
3)  No other factors were tested 
Pacheco [32] 2009 Brazil 1,538 N/A N/A 2.4 per 
100pys 
N/A 
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Table 2.1 Rates of attrition and risk factors among HIV-infected patients initiating cART (continued) 
 
First Author Year Region N Definition of 
attrition 
Active 
Follow 
up 
Ratio/Rate Risk factors for attrition 
Chasombat 
[28] 
2009 Thailan
d 
81,96
0 
Patients who were 
late for clinic visit >3 
months 
No 8.8% N/A 
Ndiaye [38] 2009 French 1,007 N/A Yes 3.5 per 
100pys 
1)age<30, IDU,  no phone number, no 
primary care, higher baseline CD4, lower 
recent CD4 and no cART were associated 
with attrition 
2) No other factors were tested 
Mocroft [37] 2008 French 12,304 No follow up visit 
and no CD4 , no VL 
and no death 
Yes 3.72 per100 
pys (3.58-
3.86) 
1)male, younger age, IDU, no ART  and 
recent CD4  were associated with attrition 
2)race was not associated with attrition 
3)  No others were tested 
Lebouche [27] 2006 French 1,756 Not attended our 
clinic or another 
clinic >1year 
Yes 4.3 per 100 
pys 
1) age<30y, IDU, homeless,  ART <1997, 
lack of primary care and AIDS in 
enrollment and psychiatric disease history 
were associated with attrition 
2) gender, baseline CD4, unemployment 
were not associated with attrition 
Lanoy [35] 2006 French 34,835 Patients who had no 
further visit during 
12 months after their 
last visit in 1999 
Yes 8.5% overall 
; 16.8% <1 yr 
vs. 7.1%> 
1yr 
diagnosed 
Diagnosed recently: Non-AIDS immigrant  
and High VL were associated with attrition 
but not lower recent CD4; 
 Diagnosed >1 year: young age, immigrant, 
IDU were associated with while lower 
recent CD4, High VL not; 
Haddow [34] 2003 UK 94 Patients who 
enrolled in our HIV 
clinic within 15 
months but not 
received 12 months 
N/A N/A 1)Age was associated with attrition 
2) gender, race, AIDS stage were not 
associated 
3) no others were tested 
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Table 2.1 Rates of attrition and risk factors among HIV-infected patients initiating cART (continued) 
 
First Author Year Region N Definition of 
attrition 
Active 
Follow 
up 
Ratio/Rate Risk factors for attrition 
Brown [47] 2006 USA 1,052 patient who missed 
all study visits and 
could not be 
contacted for 12 
consecutive months, 
who had not died 
and who did not re-
enter the study at a 
later date 
Yes 3 per 100 pys 1)Younger age, lower education level, 
unemployed, bad baseline health status, 
heterosexual contact were associated with 
attrition; 
2)gender and race were not associated 
3) no others were tested  
Yehia [36] 2008 USA 13,833 Missing follow up 
for 6 months or 1 
years 
Yes 15% per year 
(5-25%) 
N/A 
Ioannidis [30] 1997 USA 1,609 N/A Yes 3%-34% 
during 7 
years 
1)Young age, race, IDU were associated with 
attrition; 
2) baseline CD4 was not associated 
3) no others were tested 
Coleman [48] 2007 USA 495 N/A Yes 14% in 4yrs 1)minority, insurance net, no medical social 
work, recent CD4 and higher VL  were 
associated with attrition 
2) age were not associated with attrition 
3)no others were tested 
Maskew [39]  2007 South 
Africa 
5,849 Missing 2 months Yes 2.6% 1) financial 
 
  
2
4 
Table 2.2 Trend of mortality among HIV-infected patients initiating ART 
 
Authors Years for 
study 
Region (study) N AIDS 
Diagnosis 
Survival Trend 
Yang [127] 1984-2005 Taiwan 10,162 N Decreased mortality:10.2/100 pys in the pre-
HAART;6.5&3.7/100pys in the early and late HAART 
Krentz  
[72] 
1984-2003 Canada N/A N Decreased mortality:11.7/100pys in pre-HAART decreased 
to 2.4 /100pys in the HAART 
Mocroft 
[19] 
1994-2002 EuroSIDA 9803 N Decreased the risk of all deaths: 0.66RH in the late-HAART 
era,  while 1.29 HR in the pre-HAART 
CASCADE 
[128] 
1986-1998  CASCADE 5646 N Decreased the risk of deaths:64% compared with pre-
HAART 
Maria 
[129] 
1980-1997 Italy 1535 N Decreased the risk of deaths: 0.54 RH in 1997 compared 
with that in the 1991. 
Correl 
[130] 
1990-1997 Australia 346 N Decreased the risk of death: 0.20 RH in early HAART 
compared with pre-HAART 
Detels [13] 1984-1997 USA 536 N Decreased the risk of death:0.62 during HAART compared 
with pre-HAART(monotherapy) 
Murphy 
[131] 
1995-1999 VATS 528 N Decreased mortality: decreased from 0.88 event/py to 0.26 
event/py during taking HAART 
Palella [16] 1994-1997 USA 1255 N Decreased mortality : decreased from 29.4 /100pys to 8.8 
/100pys 
Vittinghoff 
[132] 
NA San Francisco 622 N Decreased the risk of death: 0.45 during 1996 calendar year 
Schwarcz  
[79] 
1987-1996 San Francisco 15,271 Y Median survival time increased 
Pezzotti  
[78] 
1985-1997 Italy 1,683 Y Median survival time increased  from 2.9 in before 
diagnosed in1987 to 15 months  diagnosed in 1996-1997 
McNaghten 
[77] 
1990-1997 USA 19,565 Y Median survival time increased 
Lee [76] 1984-1997 USA 394,705 Y Median survival time increased from 11 months for 1984 
diagnoses to 46 months for 1995 diagnoses. 
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Table 2.2 Trend of mortality among HIV-infected patients initiating ART (continued) 
 
Authors Years for 
study 
Region (study) N AIDS 
Diagnosis 
Survival Trend 
Gange [14] 1994-1999 USA 1,691 Y Decreased mortality:  decreased from19.47/100pys during 
1995 to 6.32/100pys 
Fordyce 
[82] 
1990-2001 NYC, USA 79,878 Y Cumulative survival increased from 43% diagnosed during 
1990-95 to 76% during 1996-98 
Dore [81] 1993-2000 Australia 4,351 Y Median survival time increased from 19.6 months before 
HAART to 39.6 months 
Nash [83] 1993-2001 NYC, USA 93,585 Y Death rates substantially decreased. 
Del Amo 
[133] 
1985-2003 Spain 585 N Decreased the risk of death: decreased 72% during 1997-
2000 and 83% during 2001-03 compared with 1993-96 
Smit [84] 1982-2000 Netherlands 2,305 Y More than 10 times of AIDS death after introduction 
HAART. 
Couzigou 
[80] 
1994-2002 France 4,158 Y Decreased mortality. 
Perez-
Hoyos [74] 
1996-2003 GEMES 1,129 N Decreased the risk of death: 0.55 HR during 1998-99 and 
0.40 HR during 2000-2003. 
Palella [73] 1996-2004 HOPS 6,945 Y Decreased death AIDS-related: decreased from 3.79/100 pys 
in 1996 to 0.32/100pys in 2004 
CASCADE 
[75] 
Pre1997-
2001 
CASCADE 7,740 N Decreased the risk of death: 0.47HR in 1997 and 0.16 in 
2001 
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Table 2.3 Risk factors for mortality among HIV-infected patients initiating cART 
 
Author N Age Gender Race Baseline weight 
/BMI 
Baseline 
CD4 
Baseline 
Hemoglobin 
HIV 
exposure 
Sieleunou [85] 1,187 - Y - Y Y Y - 
Etard [86] 404 N N - Y Y Y - 
Zachariah [99] 2,316 N Y - Y Y - - 
Johannessen [88] 320 N Y - Y - Y - 
Bussmann [89] 633 - - - - Y Y - 
Severe [90] 910 - Y - Y Y - - 
Weidle [91] 254 - - - - Y - - 
Coetzee [92] 287 N Y - - Y - - 
Chasombat [28] 58,008 Y Y - Y Y - - 
Pacheco [32] 1,538 N Y - - Y - Y 
Stringer [93] 21,755 N Y - Y Y Y  
Silverberg [94] 4,686 N N N - Y - - 
Taiwo [95] 122 - - - - Y - - 
Ojikutu [96] 309 N N -  Y - - 
Lawn [97] 2,423 Y N - - Y - - 
Russell [98] 1,350 N N - - Y Y - 
Zachariah [99] 1,507 N N - Y Y - - 
May [100] 10,331 Y Y - Y Y - - 
Cook [108] 1,690 - - Y - - - Y 
Colebunder [107] 1,366 N N - - - - Y 
Hsu [109] 8,410 Y N Y - - - Y 
Keruly [110] 959 Y - N - - - Y 
Pezzotti [101] 3,169 N N - - Y - Y 
ART-LINC & 
ART-CC[18] 
27,027 N Y - - Y - - 
ART-CC [102] 14,208 - - - - Y - - 
*Note: “Y” stands for statistical significance; “N” stands for no statistical significance; “-” represents no investigation for that study. 
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Figure 2.1 Geographic Distribution of Cumulative HIV Cases Reported in China through 2009  
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III. METHODS 
Study Population 
The patients for this dissertation are from a nationwide, ongoing, prospective study, 
NFATP, through which patients with HIV in China have been receiving free antiretroviral 
therapy since the end of 2002 [134]. The NFATP was established by the Division of 
Treatment and Care in the NCAIDS, Chinese Center for Disease Prevention and Control in 
response to the HIV epidemic in China. 
All individuals receiving cART as part of the NFATP between 1 January 2003 and 31 
December 2010 (n=79,750) were eligible for this study. According to the first edition of 
China Free ART Manual, NFATP enrolled HIV-infected patients age 18 years or greater, 
with CD4 cell counts less than 200 cells/ul, or WHO stage III or IV disease. At the beginning 
of 2008, the criteria for CD4 cell count was extended to include anyone with a CD4 less than 
350 cells/ul in accordance with WHO guidelines [135]. Previous studies have reported on the 
baseline characteristics and clinical outcomes among patients with HIV who enrolled in this 
cohort [53]. In brief, as of August 2008, the study subjects were 42% female, 82% rural and 
75% married. The median age at enrollment was 38 years (Interquartile range [IQR] 33 to 
46). The median weight was 53 kg for females and 59 kg for males. The main transmission 
mode was through blood or plasma donation or transfusion (53%). The median baseline CD4 
cell count was 118 cells/mL (IQR: 37 - 203) and median hemoglobin level was 12.0 mg/L 
(IQR:11.0 - 14.0) [53]. 
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Data Collection 
Detailed descriptions relevant to the administration, procedures and methods for the 
NFATP program have been published [134, 136, 137]. The program uses standardized case 
report forms (CRF) including initial patient assessment, treatment follow-up, treatment 
regimen change, treatment withdrawal and transfer for each patient visit. Information from 
CRFs was faxed to NFATP via DataFax (clinical DataFax System Inc., Hamilton, ON, 
Canada). At the visit when patients start ART, the standardized forms for initial patient 
assessment is completed. Subsequent follow up visits are arranged at approximately 0.5, 1, 2, 
3 months and once every 3 months, thereafter, and the CRF for treatment follow-up is 
completed during these visits by health providers. When the patients discontinue ART due to, 
adverse events, or are considered lost to follow-up, transfer to other clinic, or die, the CRF 
for treatment withdrawal is filled out. The information from these forms provide 
demographic information, laboratory test results, clinical symptoms and signs and self-
reported adherence [134]. Each form faxed is checked twice by the database administrators 
for discrepant logic errors and missing data. In 2010, a web-enabled electronic data 
collection system was implemented, which includes the same information as was previously 
faxed. 
The provision of free ART in China includes multiple levels of the health care 
delivery system, each of which plays different roles in the process of providing treatment to 
each patient. ART provision is at the county level while routine follow-up, monitoring and 
care are provided at a village or township level. In addition, clinicians at the county and 
prefecture level are responsible for diagnosing adverse events, opportunistic infections (OI) 
and other HIV and ART complications. Provincial and national level health facilities act as 
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consultative referral centers. All the health workers and clinicians in charge of patients 
receiving ART are trained by their own provincial centers for disease control (CDC) branch. 
Information on death, including reason and date of death, is available through the 
NFATP treatment withdrawal forms. These forms are also completed by local health workers 
and sent to central NFATP offices by DataFax (Clinical DataFax Systems, Hamilton, 
Ontario, Canada). Forms were completed on all patients known to have died at the local level 
through passive surveillance. Mortality data for the general Chinese population was obtained 
from China Health Statistic Year Book 2004 to 2010. 
 
Measurements and Statistical Analyses for Aim 1 
Specific AIM 1: To describe and evaluate attrition following cART initiation in China, 
2003-2010. 
Identification of attrition: Attrition was defined as not having a visit for at least 210 
days. This is approximately seven months, which allows leniency for those who miss a 
standard three-month NFATP visit but are seen within four weeks of the following scheduled 
NFATP visit. Moreover, this seven month definition is roughly similar to the definition of six 
months used in prior studies [46, 138]. (Note: if patients miss a scheduled appointment, CDC 
health workers or physicians who are in charge of the treatment try to contact the patients by 
telephone or visit the address left by patients.) 
Covariates: All information about the outcome variable and covariates were obtained 
from the CRFs completed by local health workers (Table 3.1). The factors measured at 
baseline included age, gender, marital status, HIV exposure category, type of health care 
setting (general hospital, infectious diseases hospital, centers for diseases control clinic, 
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health care center at township level, village clinic and prison hospital) region (eastern, central 
and western region), calendar year of cART initiation, CD4 cell count, alanine 
aminotransferase and hemoglobin level. Baseline symptoms included on the CRF included 
fever, cough, sputum production, dyspnea, chest pain, night sweat, diarrhea, nausea, 
projectile vomiting, headache, declining vision, blurred vision, rash, thrush, oral hairy 
leukoplakia, and lymphadenopathy. For this study, baseline symptom severity was defined by 
counting the number of symptoms present at baseline. The initial therapy regimens consisted 
of zidovudine(AZT)/ stavudine (d4T) + didanosine (ddI)+ nevirapine (NVP) between 2003 
and 2005. After 2005, the initial regimens were gradually replaced with AZT/d4T+ 
lamivudine (3TC) + NVP. In this study, we also evaluated the initial cART regimen by 
classifying regimens based on whether or not they included 3TC. 
Statistical Analysis: 
We first described the study population based on the following demographic and 
clinical characteristics measured at baseline (time of cART initiation): age, gender, HIV 
exposure category, marriage status, type of health care setting, region, CD4 cell count, 
weight, hemoglobin, alanine aminotransferase, symptom category, initial cART regimen and 
calendar year of starting cART. We described the overall time to the first attrition event 
among all patients. Then we will use Kaplan-Meier product limit methods to assess the effect 
of each factor of interest on time to attrition. We used the log-rank test to compare curves. 
Cox proportional hazard models were used to estimate unadjusted and adjusted hazard ratios 
with 95% confidence interval. The proportional hazard assumption was evaluated by a plot of 
log (-log survival) versus log time. We also fit adjusted Kaplan-Meier curves as indicated. 
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Aim 1a: To identify independent risk factors associated with time from cART 
initiation to attrition. 
 For Aim 1a we used a predictive analysis strategy to identify independent predictors 
of attrition. Based on the bivariable analyses, we identified factors predictive of the outcome 
with a p-value<0.2. These factors were entered into a full model. Backward elimination was 
used to remove covariates. The final model only included factors independently predictive of 
the outcome defined as a p-value<0.05. Given the relationship between type of antiretroviral 
therapy available through NFATP and calendar year of starting cART, we explored the 
relationship between type of therapy and attrition in models stratified by calendar year of 
cART initiation. As a sensitivity analysis we administratively censored follow-up time at 12 
and 24 months following cART initiation rather than at 31 December 2010. All hypothesis 
testing was 2-sided, with α level of 0.05. 
Aim1b and 1c: To evaluate (1b) the effect of calendar year of starting cART (1c) the 
effect of type of health care setting on time to attrition.  
For Aim 1b we specifically evaluated the effect of calendar year of starting cART on 
time to attrition. The methods were analogous to those in Aim 1a, except we fit a traditional 
epidemiologic model. In these analyses we assessed for effect measure modification by the 
likelihood ratio test, and confounders were identified using a change-in estimate of 10%. The 
analyses for Aim 1c were the same as those for Aim 1b, except the main exposure of interest 
was the type of health care setting where the patient received their HIV care.  
Specific Aim 2: To describe and evaluate excess mortality among HIV-infected 
patients receiving cART in comparison to the general population in China, 2003-2009. 
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Identification of excess mortality: Excess mortality was defined as the difference in 
mortality rates between HIV-infected patients in NFATP and people from the general 
population in China, after adjusting for age, sex and calendar year. 1) All patients recorded as 
deceased in NFATP from 2003 to 2009 were included in this analysis as the number of 
observed deaths. The time to death was calculated as the time from cART initiation until 
death. Patients were right censored at the date of death or 31 December 2009, whichever 
occured first. The origin of the analysis was the start of cART for each patient. (Note: 
patients who were not eligible to initiate cART treatment were not included in NFATP). 2) 
The expected number of deaths was calculated by using the mortality rates of the general 
population in China, which were stratified by age, sex, area of residence and calendar year 
and were comparable to this study population. A previous study in China showed that 
mortality rates in NFATP were greatest during the first 3 months after cART initiation with a 
mortality rate of 22.6/100 person-year during this period and then decreasing to 4/100 
person-years after 6 months; with the same rates during the subsequent 4 years [53]. Figure 
3.1 demonstrates the mortality trend for up to 60 months following treatment initiation. 
Covariates: Factors measured at baseline included age, gender, HIV exposure 
category, type of health care setting, and CD4 count at enrollment. Also, baseline symptom 
severity was defined by counting the number of symptoms present at baseline as described in 
Aim 1. The initial regimen categories used were the same as those described for Aim 1. The 
calendar period was categorized as 2003/2004, 2005-2007 and 2008/2009. This 
categorization was chosen to: minimize heterogeneity within groups; correspond with major 
therapeutic changes across calendar time; and preserve adequate sample sizes within strata. 
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Statistical Analyses: 
We described the HIV-infected study population receiving cART across calendar 
periods, including demographic factors, clinical characteristics at cART initiation, and 
duration of follow-up.  
We calculated the observed deaths, person-years of follow-up and the overall 
mortality rate and 95% CI by calendar periods. The overall mortality rate was calculated as 
the observed number of deaths divided by person-time in each calendar year and reported per 
1000 person-years. We then calculated the expected deaths per calendar year. We created a 
hypothetical cohort of HIV-uninfected individuals matched to the study population on age, 
sex, area of residence and calendar year of follow-up. To this hypothetical cohort we applied 
the general Chinese population mortality rates to estimate expected deaths. Expected number 
of deaths was calculated by applying annual probability of death from the general Chinese 
population to the study population considering individuals to be at risk until their actual date 
of death or censoring. 
Excess deaths were calculated by subtracting the number of expected deaths from the 
observed deaths. Excess mortality rates per calendar year of follow-up were estimated taking 
the excess deaths in each calendar year and dividing by person-years of follow-up. Excess 
mortality rates here represent the difference between the observed mortality rates of HIV-
infected patients in the study population and the expected mortality rates had these patients 
experienced the mortality rate of the general Chinese population based on their age, sex and 
calendar year of follow-up. We also calculated standardized mortality ratios (SMR). These 
were calculated as the ratio of the number of observed deaths to the number of expected 
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deaths, and the 95% confidence intervals were calculated. These were calculated stratified by 
calendar year, and demographic and clinical characteristics. 
Multivariable analyses of excess mortality were fit using Poisson models [111]. In 
this relative survival model, the observed number of deaths in each patient stratum was 
modeled with a Poisson process and we used the expected number of deaths in each stratum 
as an offset. Time was categorized in one year increments from cART initiation, assuming a 
piecewise constant hazard within each year after starting cART. Excess hazard ratios (eHRs) 
and associated 95% CIs were obtained as the antilog of the coefficient from this relative 
survival model. We examined changes in relative survival across calendar time adjusting for 
age, sex, HIV-exposure category, CD4 count, initial cART regimen, type of health care 
setting and area of residence. 
 
Power Calculation 
Given this study relied on existing data we calculated power that each aim of this 
study would have. We assumed at most a total sample size of 79,750, corresponding to the 
maximum number of patients who received free cART through NFATP between 2003 and 
2009. For all power calculations we used a two-sided test with a 0.05 significance level.  
First, to illustrate the power available to evaluate risk factors associated with time to 
attrition, we used IDU as an example. We used a log-rank test to test for a statistically 
significant difference between the two survival curves comparing patients exposed to HIV 
through IDU versus patients exposed through all other transmission categories. We varied the 
proportion of the study population with IDU from 10% to 30%. We then calculated the 
expected power for a range of possible hazard ratios (Table 3.2). For example, with 30% of 
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the study population with IDU, this study has over 80% power to detect a hazard ratio 
comparing IDU to non-IDU patients of time to attrition of at least 1.25. In comparison we 
will have over 80% power to detect a hazard ratio of at least 1.4 even if less than 10% of the 
study population was infected via IDU.  
Next, for the evaluation of factors associated with mortality, the index group or 
reference group was defined based on year of initiation of ART. We used calendar year 2003 
as the reference group compared with 2004. We then ranged the expected hazard ratios and 
calculated expected power (Table 3.3). For example, with 25% of patients receiving cART in 
2003, we would have over 80% power to detect a hazard ratio of at least 1.2. Table 3.3 lists 
the power expected based on varying the expected hazard ratios between two calendar years 
for one year follow up. Again, our study has enough power to detect even relatively small 
differences in mortality rates across calendar years. 
 
Human Subjects 
This study was a secondary data analysis project and had no direct contact with 
human subjects. Written informed consent was obtained from the subjects when they 
accepted treatment and care under NFATP run by the Division of Treatment and Care in the 
National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control 
and Prevention (NCAIDS/CCDC). This study was approved by the Institutional Review 
Board at the University of North Carolina at Chapel Hill. The data used for this study did not 
include any personal identifiers and therefore, the risk to breach of patient confidentiality was 
minimal. The data were stored on one computer with an encrypted hard disk drive. All other 
data, electronic and original paper version, are only available to NFATP staff in China.  
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Table 3.1 Variables list 
 
Variables  Variable Description Type 
   
Outcome variables (Aim1)   
Time to attrition Time from initiating cART to attrition which is defined as any 
patient with HIV infection initiating cART who has the 
duration more than or equal to 210 days since a scheduled visit.  
Continuous 
   
Outcome variables(Aim2)  
Number of excess death Number of excess death calculated by number of observed 
death minus number of expected death  
Continuous 
   
   
Covariates   
Age Age during the enrollment Continuous 
Gender Gender [0=male, 1=female] Binary 
Marital status Marital status [0=single, 1=married, 2=divorced,3= widowed ] Categorical 
HIV exposure group HIV exposure group [ 1=blood or plasma, 2=IDU, 3=MSM, 
4=Heterosexual, 5=MTC, 9=unknown. 
Categorical 
Type of health care settings Type of health care setting  [1=Comprehensive hospitals, 2= 
Infectious-disease hospitals, 3=Centers for diseases control, 4= 
township hospital, 5=Clinics in village, 6=others]  
Categorical 
Baseline symptom categories Numbers of symptoms appearance during enrollment 
[0=none,1=1 type, 2=2-3types,3=4-5types 
Categorical 
CD4 cell count  CD4 cell count measured at enrollment  Continuous 
Hemoglobin count Hemoglobin count measured at enrollment Continuous 
Alanine aminotransferase Alanine aminotransferase measured at enrollment Continuous 
Body weight Body weight measured at enrollment Continuous 
Calendar year to initiate cART Calendar year when patients initiated cART Categorical 
Initial regimens The initiation of regimens [0=3TC based regimens, 1=Non-3TC 
based regimens] 
Binary 
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Table 3.2 Power calculated by assumed Hazard ratios of attrition among the index group and the 
reference group. 
 
Proportion Exposed Hazard ratios Power obtained 
10% 1.10 11% 
 1.20 31% 
 1.30 58% 
 1.40 82% 
 1.50 95% 
 1.60 99% 
20% 1.10 15% 
 1.20 44% 
 1.25 60% 
 1.30 76% 
 1.40 94% 
 1.50 99% 
30% 1.10 21% 
 1.15 40% 
 1.20 61% 
 1.25 80% 
 1.30 91% 
 1.35 97% 
 
Table 3.3 Power calculated by assumed mortality rates among the index group and the reference 
group. 
 
Proportion Exposed Hazard ratios Power obtained 
20% 1.05 10% 
 1.10 27% 
 1.15 51% 
 1.20 75% 
 1.25 91% 
 1.30 98% 
25% 1.05 11% 
 1.10 30% 
 1.15 57% 
 1.20 81% 
 1.25 94% 
 1.30 99% 
30% 1.05 14% 
 1.10 39% 
 1.13 58% 
 1.15 70% 
 1.20 91% 
 1.25 98% 
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Figure 3.1 Mortality rate per 3-months interval among HIV-infected patients receiving cART from 
June 2002 to August 2008 in China 
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IV. ATTRITION AMONG HUMAN IMMUNODEFICIENCY VIRUS (HIV)-INFECTED 
PATIENTS INITIATING ANTIRETROVIRAL THERAPY IN CHINA, 2003 – 2010 
 
Introduction  
Local, national and international efforts have strived to make combination 
antiretroviral therapy (cART) available to patients with human immunodeficiency virus 
(HIV) around the globe, including China [100, 120, 139]. With these efforts and the 
increasing effectiveness of provided cART, mortality and morbidity from HIV has 
dramatically decreased in high- and low-income areas of the world [17, 18, 53]. However, 
some patients may not benefit from cART because of inadequate access to HIV care, 
including attrition after care initiation [37, 39, 140]. Estimates of attrition depend in large 
part on the definition of attrition used, the location and nature of the study population, and 
other study characteristics [25, 28, 35, 43].  
Among HIV-infected patients initiating cART living in high-income areas of the 
world, attrition rates can be as low as 5% during the first year of treatment [18]. Studies 
conducted among patients living in low-income areas of the world have observed up to 50% 
attrition to HIV care, with many of these patients not returning to care because of death 
[141]. Better understanding of attrition among HIV-infected patients in care is essential to 
evaluating HIV clinical care provision and informing interventions for improving retention in 
care [142]. Retention in care could help improve individual clinical outcomes [143] and 
reduce risk of further HIV transmission in the community [144].  
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There were an estimated 740,000 HIV-infected patients living in China as of 2009 
[145]. The major routes of HIV transmission in China include injection drug use (IDU), 
blood transfusion/former plasma donation, and heterosexual contact [146]. China initiated 
free cART provision through the National Free Antiretroviral Treatment Program (NFATP) 
in 2002. As of the end of 2009, over 80,000 HIV-infected patients had received cART 
through NFATP [53]. The effectiveness of this program in reducing mortality has been 
described previously [147, 148]. However, little is known about retention in HIV care among 
HIV-infected patients in China. The purpose of this study was to describe temporal trends in 
attrition and identify factors associated with greater risk of attrition among patients receiving 
cART through the Chinese NFATP Program from 2003 to 2010.  
 
Methods 
Study population 
The study population included all HIV-infected patients receiving cART through the 
Chinese NFATP from 1 January 2003 to 31 December 2010. The NFATP is managed by the 
Division of Treatment and Care in the National Center for AIDS/STD Control and 
Prevention, Chinese Center for Disease Control and Prevention. Detailed descriptions 
relevant to the management, process and methods of the Chinese NFATP have been 
published [134, 149]. The program used standardized paper based case report forms which 
were completed by local health workers and then faxed to a central office in the Division of 
Treatment and Care [135]. In 2010, a web-enabled electronic data collection system was 
implemented. At the visit when patients start cART, a standardized form for initial patient 
assessment is completed and baseline information is collected, including demographic data, 
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suspected HIV infection exposure route, clinical symptoms and signs, and laboratory test 
results. Subsequent follow up visits are scheduled for 2, 4, 8 and 12 weeks following cART 
initiation, and then every 3 months thereafter.  
From its inception, NFATP provided free cART to all HIV-infected patients with a 
CD4 cell counts below 200 cells/ μL, a total lymphocyte counts <1200 cells/ μL or a World 
Health Organization (WHO) stage III or IV. At the beginning of 2008, patients with CD4 cell 
counts <350 cells/ μL became eligible for free cART in accordance with updated WHO 
guidelines [135].  
For these analyses we included all HIV-infected adults who were ART-naïve at the 
time they initiated free cART through NFATP. Henan Province did not submit data to 
NFATP until July 1, 2006; therefore, patients residing in Henan Province who initiated 
cART before that date were excluded from this analysis (n=16,609) [150]. Additionally we 
excluded patients who did not have any recorded follow-up (n=2,896), consistent with prior 
work in this area [151], and those who initiated cART less than 210 days (approximately 
seven months) prior to 31 December 2010 to allow for adequate follow-up (n=14,195). 
This study was approved by the Institutional Review Board at the University of North 
Carolina at Chapel Hill. 
Measurements 
Attrition was defined as not having a visit for at least 210 days. This is approximately 
seven months, which allows leniency for those who miss a standard three-month NFATP 
visit but are seen within four weeks of the following scheduled NFATP visit. Moreover, this 
seven  month definition is roughly similar to the definition of six months used in prior studies 
[46, 138]. In sensitivity analyses, we assessed the effect of using different time intervals to 
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define attrition, including 180, 270 and 360 days from last observation. Factors measured at 
baseline included age, gender, marital status, suspected HIV exposure route, initial cART 
regimen, CD4 cell counts, alanine aminotransferase and hemoglobin at cART initiation. 
Baseline symptoms recorded include fever, cough, sputum production, dyspnea, chest pain, 
night sweat, diarrhea, nausea, projectile vomiting, headache, declining vision, blurred vision, 
rash, thrush, oral hairy leukoplakia, and lymphadenopathy. For these analyses, we summed 
the number of symptoms reported for each patient as a measure of clinical symptom severity. 
Antiretroviral therapy regimens were categorized as: neviripine (NVP) with lamivudine 
(3TC) and either zidovudine (AZT) or stavudine (D4T); efavirenz (EFV) with 3TC and either 
AZT or D4T; NVP and didanosine (DDI) and either AZT or D4T; and all other regimens. 
Health care setting (general hospital, infectious diseases hospital, centers for diseases control 
clinic, health care center at township level, village clinic and prison hospital), area of 
residence (eastern, central and western region) and calendar year of cART initiation were 
also included.   
Statistical analysis  
Person-time was calculated as time from cART initiation to the first of attrition or 
date of censoring. Patients were censored at the date of death or 31 December 2010, 
whichever occurred first. The complement of the Kaplan-Meier survival curve was used to 
plot the cumulative incidence of attrition by levels of factors of interest. The log-rank test 
statistic was used to assess differences in survival curves.  
Cox proportional hazard models were used to estimate unadjusted and adjusted 
hazard ratios and 95% confidence intervals (CI), and we assessed for deviations from the 
proportional hazard assumption. Based on the bivariable results, we identified factors 
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predictive of the outcome with a P value<0.2. These factors were jointly entered into a 
model. Then backward elimination was used to sequentially to remove covariates with the 
highest P-values such that the final model included only factors predictive of the outcome 
defined as a P value<0.05.  
Given the relationship between type of antiretroviral therapy available through 
NFATP and calendar year of starting cART, we explored the relationship between type of 
therapy and attrition in models stratified by calendar year of cART initiation. As a sensitivity 
analysis we administratively censored follow-up time at 12 and 24 months following cART 
initiation rather than at 31 December 2010. Data were analyzed using SAS version 9.2 (SAS 
Institute, Cary NC, USA). All hypothesis testing was 2-sided, with α level of 0.05.  
 
Results 
Between 1 January 2003 and 31 May 2010, 67,732 HIV-infected patients who 
initiated cART through the Chinese NFATP were included in this analysis. Over one-third 
(37%) of patients were women, 51% were infected through heterosexual contact, 23% 
through blood transfusion/ former plasma donation, and 22% through IDU (Table 4.1). At 
cART initiation, the median age was 38 years (interquartile range [IQR]: 32 - 45), and the 
median CD4 cell counts was 131 cells/ μL (IQR: 42 - 220). The median year of cART 
initiation was 2008 (IQR: 2007 - 2009). The initial cART regimen prescribed was 
predominantly NVP and 3TC with either AZT or D4T (70%).  
Patients contributed a median of 20 months of follow-up (IQR: 11 - 34) and 8 visits 
(IQR: 5 - 13). The overall person-time contributed was 137,792 person-years. Of the 67,732 
HIV-infected patients, 9,969 were lost to HIV care, and the remaining 57,763 were 
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administratively censored (7,390 of these 57,763 were censored at death). Among those 
administratively censored the median time on study was 22 months (IQR: 13 - 37), and 
among those who died the median time to death was 4 months (IQR: 1 - 11). The cumulative 
probability of attrition from cART initiation was 9% at 12 months, 13% at 18 months, 16% at 
24 months and 24% at 60 months (Figure 4.1).  
A number of factors were associated with attrition in unadjusted analyses, including 
younger age, male gender and being single or divorced (Table 4.2). Patients infected through 
IDU were more than twice as likely to be lost to HIV care [crude Hazard Ratio (cHR) 2.20, 
95% CI: 2.10, 2.30] as those infected by heterosexual contact (Figure 4.2). Patients initiating 
cART in the central region of China were less likely to be lost to HIV care than patients 
living in other areas of China, and patients who received HIV care at larger and more 
centralized health care settings were more likely to be lost to care than patients receiving care 
at village level clinics. In multivariable analyses the direction of these relationships persisted 
although some were notably attenuated, particularly the association between attrition and 
type of health care setting.  
Patients with higher CD4 cell counts at cART initiation were more likely to be lost to 
care (Figure 4.3). The hazard of attrition among patients with CD4 cell counts greater than 
350 cells/ μL was 1.6 times greater than for patients with CD4 cell counts less than 50 cells/ 
μL (cHR=1.57; 95% CI:1.41, 1.74). The hazard of attrition was relatively similar among 
patients with CD4 cell counts less than 350 cells/mL at cART initiation. The relationship 
between CD4 cell count and attrition persisted after multivariable adjustment (Table 4.2). 
Patients with lower hemoglobin (cHR=1.24; 95% CI: 1.12, 1.37) and higher ALT 
(cHR=1.28; 95% CI: 1.16, 1.41) were also more likely to be lost, although ALT did not 
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remain predictive in multivariable analyses. Patients with more than four symptoms at cART 
initiation had a higher hazard of attrition, even after accounting for other characteristics. 
Notably, attrition decreased with increasing cART initiation calendar year (Figures 
4.4) and among patients who initiated modern cART regimens (including 3TC with either 
NVP or EFV) (Figures 4.5). These relationships were consistent in multivariable adjusted 
analyses (Table 4.2). To further assess the relationship between calendar year of cART 
initiation and type of regimen received, we compared cART regimens containing and not 
containing lamivudine: We observed a persistent effect of lamivudine associated with less 
attrition in models adjusting for cART initiation calendar year and those stratified by cART 
initiation calendar year (Table 4.3).  
We assessed the effect of cART initiation calendar year with varying lengths of 
follow-up: We fit models to data where we administratively censored follow-up at 12 and at 
24 months (Table 4.4). The reductions in attrition in more recent calendar years persisted in 
all models and were comparable to results observed relying on all patient observation time 
available. In additional sensitivity analyses, using different time intervals to define attrition, 
including 180, 270 and 360 days from last observation, our results were consistent 
irrespective of the definition of attrition we employed (data not shown). Finally we evaluated 
the effect of excluding patients who were only seen once by NFATP at their initial patient 
visit (n=2,896). Our results were unaltered when we included this group of patients in our 
main analyses (data not shown).  
Discussion 
At one year following cART initiation the cumulative probability of attrition was 9% 
and rose to 24% at 5 years among patients receiving free antiretroviral therapy in China 
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between 2003 and 2010 through the NFATP. This degree of retention in care is slightly better 
than that observed in low-income areas of the world (approximately 15% at one year) and 
slightly worse than that observed in high-income areas of the world (approximately 5% at 
one year) [18]. In a recent study conducted in Uganda attrition rates of 16%, 30% and 39% 
were observed at 1, 2 and 3 years following cART initiation, respectively [138].  
Attrition was associated with both individual and contextual factors. Consistent with 
prior studies patients who acquired HIV through IDU were at substantial risk of being lost to 
care. In this study 22% of patients accessing HIV care were IDU, in comparison to 39% of 
HIV infections reported nationally [146]. This observation highlights that IDU encounter 
problems with both initiating and remaining in HIV care. In contrast to previous studies 
where either CD4 cell counts did not affect attrition or patients with lower CD4 cell counts 
had poorer retention [26, 37], among Chinese patients in NFATP we observed greater 
attrition among patients with higher CD4 cell counts. This result suggests that unrecognized 
mortality may not be a substantial underlying cause of attrition in this study population. 
However, attrition was higher among patients with lower hemoglobin, which has been 
associated with greater mortality [100, 151]. 
We observed encouraging results that in more recent calendar years and with the 
provision of newer cART regimens patients were retained in care longer. In multivariable 
analyses we did not observe substantial differences in attrition by type of clinic. Other studies 
conducted in low-income settings have found a similar attrition equality across large and 
small health care settings [123, 124, 152]. 
Our study is one of the largest to evaluate retention in HIV care and the only study to 
date to be carried out in China. However there are limitations to the present study. We were 
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not able to link the study population with death registries, nor was there active follow-up of 
patients lost to care. Therefore, our estimate of attrition includes patients who died but their 
death was not reported to the clinic where they were receiving HIV care. In prior studies 
conducted primarily in Africa as many as one-half of patients not returning to HIV care were 
found to be deceased when active tracing was available [24, 45, 49]. We do not know the 
outcomes of patients lost to follow-up in NFATP; however, given the relatively high CD4 
cell counts among patients lost to care it is possibly that mortality may not have been a 
primary cause of attrition from HIV care in this population. We were also unable to evaluate 
the effect of longitudinal CD4 cell counts or HIV RNA levels on retention as these data were 
not available in the early years of the NFATP program. As additional information on these 
biomarkers becomes available it will be important to evaluate how they are associated with 
retention in HIV care. Additionally, given the unique nature of the Chinese NFATP program 
our results may not generalize to clinics in other areas of the world. For example, as part of 
NFATP all patients received free antiretroviral therapy as well as other needed HIV care. In 
other settings it has been shown that retention increases in programs that offer free ART [40]. 
Finally, we were not able to take into account hepatitis B (HBV) co-infection among HIV 
patients in this study. Although we were able to assess the effect of ALT on retention this 
marker alone may not have captured the entire effect of HBV co-infection, particularly given 
the high prevalence of HBV in China [153] and its relationship to greater mortality among 
HIV-infected patients [154].  
These results have important implications for the management of HIV in China. 
Treatment of HIV, even at higher CD4 cell counts, clearly reduces transmission [144], and 
earlier treatment of HIV has measurable improvement on patient outcomes [104]. But these 
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benefits can only be achieved if HIV infection is detected, patients are efficiently referred for 
care, and following cART initiation patients remain in active clinical follow-up. Any 
substantial attrition, and certainly the level of attrition documented in this study, can erode 
the benefits of antiviral therapy and give rise to increased transmission of HIV and HIV drug 
resistance. Reassuringly to date prevalence of transmitted HIV drug resistance remains 
relatively low in China [155]. Our results identify patients most likely to be lost, and several 
factors that help to explain loss. These results must be used to design programs to keep HIV-
infected people in care, and over a very long period of time.  
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Table 4.1 Characteristics of 67,732 HIV-infected patients at combination antiretroviral therapy 
initiation, the China National Free Antiretroviral Treatment Program 2003 - 2010 
 
Characteristic         N (%) or Median (IQR) 
Age (years) 
        Median (IQR) 
            
             38 (32 - 45) 
    18-29 11509 (17%) 
    30-44 38200 (56%) 
    ≥45 18023 (27%) 
Gender  
     Female 24930 (37%) 
     Male 42798 (63%) 
Marital status  
     Single 10875 (16%) 
     Married 46434 (69%) 
     Divorced 4864 (7%) 
     Widowed 5399 (8%) 
HIV exposure  
     Blood transfusion/former plasma donation  14555 (23%) 
     Intravenous drug use 13735 (22%) 
     Homosexual transmission 2826 (4%) 
     Heterosexual transmission 32194 (51%) 
Area of residence  
     Eastern region  8359 (12%) 
     Central region 21278 (32%) 
     Western region 38095 (56%) 
Health care setting  
     General hospital 26801 (40%) 
     Infectious diseases hospital 12321 (18%) 
     Centers for diseases control clinic 16019 (24%) 
     Health care center at township level   9496 (14%) 
     Village clinic 2000 (3%) 
     Prison hospital   646 (1%) 
CD4 counts (cells/ μL)  
         Median (IQR)           131 (42 - 220) 
         0-49 17692 (28%) 
         50-199 26648 (42%) 
         200-349 17465 (27%) 
         ≥350 1760 (3%) 
Hemoglobin (g/L)  
         Median (IQR)             124 (108 - 140) 
         0-79 2612 (4%) 
          ≥80 59269 (96%) 
ALT  (U/L)   
         Median (IQR)           28 (18 - 44) 
        ≥100 2421 (4%) 
        0-99 58875 (96%) 
. 
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Table 4.1 Characteristics of 67,732 HIV-infected patients at combination antiretroviral therapy 
initiation, the China National Free Antiretroviral Treatment Program 2003 - 2010 (continued) 
 
Characteristic N (%) or Median (IQR) 
Number of baseline symptoms   
       ≥4 18308 (27%) 
       2-3 15257 (22%) 
       1   9214 (14%) 
       0 24953 (37%) 
Initiation cART regimen  
      NVP+3TC+AZT 22179 (33%) 
      NVP+3TC+D4T 25336 (37%) 
      NVP+DDI+AZT 2557 (4%) 
      NVP+DDI+D4T  1970 (3%) 
      EFV+3TC+AZT   7052 (10%) 
      EFV+3TC+D4T   6440 (10%) 
      Other regimens 2198 (3%) 
Year of cART initiation   
      2003-2004 2182 (3%) 
      2005-2006   9880 (15%) 
      2007-2008 27149 (40%) 
      2009-2010 28521 (42%) 
Note ALT=alanine aminotransferase; cART=Combination Antiretroviral Therapy; NVP= nevirapine; 
3TC=lamivudine; AZT= zidovudine; D4T=stavudine; DDI=didanosine; EFV=efavirenz;  
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Table 4.2 Clinical and demographic characteristics associated with attrition among HIV-infected 
patients at combination antiretroviral therapy initiation, the China National Free Antiretroviral 
Treatment Program 2003 - 2010 
 
Characteristic Unadjusted HR 
 (95% CI) 
*Adjusted HR  
(95% CI) 
Age (years)   
     18-29 1.52 (1.43 -1.61) 1.10 (1.02 - 1.19) 
     30-44 1.28 (1.22 -1.34) 0.94 (0.88 - 1.00) 
     ≥45 1 1 
Gender   
     Male 1.30 (1.24 - 1.35) 1.09 (1.03 - 1.15) 
     Female 1 1 
Marital status   
     Divorced 1.41 (1.31 - 1.51) 1.30 (1.20 - 1.41) 
     Single 1.62 (1.55 - 1.70) 1.26 (1.18 - 1.34) 
     Widowed  0.95 (0.88 - 1.03) 1.10 (1.01 - 1.21) 
     Married  1 1 
HIV exposure   
     Blood transfusion/former plasma donation 0.83 (0.78 - 0.88) 0.74 (0.67 - 0.82) 
     Intravenous drug use 2.20 (2.10 - 2.30) 1.87 (1.76 - 1.98) 
     Homosexual transmission 0.53 (0.45 - 0.62) 0.52 (0.43 - 0.61) 
     Heterosexual transmission 1 1 
Area of residence   
     Eastern region 0.92 (0.86 - 0.97) 1.04 (0.96 - 1.12) 
     Central region 0.61 (0.58 - 0.64) 0.67 (0.61 - 0.74) 
     Western region 1 1 
Health care setting   
     General hospital 2.60 (2.22 - 3.05) 1.19 (0.96 - 1.48) 
     Infectious diseases hospital 2.09 (1.77 - 2.46) 1.09 (0.87 - 1.36) 
     Centers for diseases control clinic 1.67 (1.42 - 1.96) 1.02 (0.82 - 1.27) 
     Health care center at township level 1.78 (1.50 - 2.10) 1.42 (1.15 - 1.76) 
     Prison hospital 5.99 (4.89 - 7.33) 2.33 (1.80 - 3.01) 
     Village clinic 1 1 
CD4 counts (cells/ μL)   
     ≥350 1.57 (1.41 - 1.74) 1.76 (1.55 - 2.00) 
     200-349 1.12 (1.06 - 1.19) 1.07 (1.00 - 1.14) 
     50-199 1.01 (0.96 - 1.06) 0.99 (0.93 - 1.05) 
     0-49 1 1 
Hemoglobin (g/L)   
     0-79 1.24 (1.12 - 1.37) 1.24 (1.10 - 1.39) 
     ≥80 1 1 
ALT (U/L)    
     ≥100 1.28 (1.16 - 1.41)  
     0-99 1  
Number of baseline symptom    
     ≥4 1.07 (1.02 - 1.13) 1.07 (1.01 - 1.14) 
     2-3 0.95 (0.90 - 1.00) 0.98 (0.92 - 1.04) 
     1 0.96 (0.90 - 1.02) 0.96 (0.89 - 1.04) 
     0 1 1 
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Table 4.2 Clinical and demographic characteristics associated with attrition among HIV-infected 
patients at combination antiretroviral therapy initiation, the China National Free Antiretroviral 
Treatment Program 2003 - 2010 (continued) 
 
Characteristic Unadjusted HR  
(95% CI) 
*Adjusted HR  
(95% CI) 
Initiation cART regimen   
      NVP+3TC+AZT 0.90 (0.83 - 0.97) 0.95 (0.88 - 1.03) 
      NVP+3TC+D4T 0.92 (0.85 - 0.99) 0.86 (0.79 - 0.93) 
      NVP+DDI+AZT 1.19 (1.07 - 1.33) 1.58 (1.35 - 1.86) 
      NVP+DDI+D4T 1.18 (1.06 - 1.32) 0.92 (0.77 - 1.10) 
      EFV+3TC+AZT 1 1 
      EFV+3TC+D4T 0.89 (0.81 - 0.98) 0.83 (0.75 - 0.92) 
      Other regimens 1.32 (1.18 - 1.47) 1.29 (1.12 - 1.48) 
Year of cART initiation    
     2003-2004 2.24 (2.05 - 2.44) 3.29 (2.84 - 3.81) 
     2005-2006 1.71 (1.61 - 1.82) 1.70 (1.58 - 1.83) 
     2007-2008 1.31 (1.24 - 1.38) 1.25 (1.17 - 1.32) 
     2009-2010 1 1 
*Adjusted hazard ratios are based on one model including all characteristics listed in column except 
ALT. Note: HR = hazard ratio; 95% CI = 95% Confidence Interval; ALT=alanine aminotransferase; 
cART=Combination Antiretroviral Therapy; NVP= nevirapine; 3TC=lamivudine; AZT= zidovudine; 
D4T=stavudine; DDI=didanosine; EFV=efavirenz.  
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Table 4.3 Association between initial combination antiretroviral regimen (Lamivudine /Non-
lamivudine) and time to attrition overall and stratified by calendar year of therapy initiation 
 
 HR (95% CI) 
Unadjusted   
                     Non-lamivudine 1.33 (1.25 - 1.41) 
                     Lamivudine 1.00 
Adjusted all factors but NOT calendar year†  
                     Non-lamivudine 1.81 (1.65 - 1.98) 
                     Lamivudine 1.00 
Adjusted all factors and calendar year ‡  
                     Non-lamivudine 1.39 (1.26 - 1.54) 
                     Lamivudine 1.00 
Adjusted stratified by calendar year of cART initiation*  
              2003-2004 
 
                     Non-lamivudine N/A** 
                     Lamivudine N/A** 
              2005-2006  
                     Non-lamivudine 1.44 (1.24 - 1.67) 
                     Lamivudine 1.00 
              2007-2008  
                     Non-lamivudine 1.81 (1.55 - 2.11) 
                     Lamivudine 1.00 
              2009-2010  
                     Non-lamivudine 1.41 (0.97- 2.07) 
                     Lamivudine 1.00 
Note: HR=hazard ratio; 95% CI=95% Confidence Interval; †Includes initial regimen (lamivudine 
/Non-lamivudine) and patients’ age, gender, marriage status, HIV exposure category, CD4 cell 
counts, hemoglobin level, clinical symptoms, area of residence, health care setting but excludes the 
year of starting therapy. ‡ Includes all factors plus the year of starting therapy. * Includes all factors 
but stratifies by the year of starting therapy. ** Because lamivudine was only available after 2005 in 
China; therefore we did not make estimates during 2003-2004. 
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Table 4.4 Association between the calendar year of combination antiretroviral therapy initiation and 
time to attrition stratified by observation time 
 
 HR (95% CI) 
Follow-up time truncated at 12 months of follow-up: 
Unadjusted   
2003-2004 2.18 (1.92 - 2.48) 
2005-2006 1.81 (1.68 - 1.96) 
2007-2008 1.30 (1.22 - 1.39) 
2009-2010 1.00 
Adjusted all factors but NOT initial 
regimens† 
 
2003-2004 4.28 (3.57 - 5.14) 
2005-2006 1.77 (1.61 - 1.93) 
2007-2008 1.20 (1.12 - 1.29) 
2009-2010 1.00 
Adjusted all factors and initial regimens‡  
2003-2004 4.08 (3.35 - 4.96) 
2005-2006 1.85 (1.68 - 2.03) 
2007-2008 1.23 (1.14 - 1.32) 
2009-2010 1.00 
Follow-up time truncated at 24 months of follow-up: 
Unadjusted   
2003-2004 2.23 (2.03 - 2.46) 
2005-2006 1.74 (1.64 - 1.86) 
2007-2008 1.29 (1.23 - 1.37) 
2009-2010 1.00 
Adjusted all factors but NOT initial 
regimens† 
 
2003-2004 3.58 (3.09 - 4.16) 
2005-2006 1.72 (1.60 - 1.85) 
2007-2008 1.22 (1.15 - 1.30) 
2009-2010 1.00 
Adjusted all factors and initial regimens‡  
2003-2004 3.14 (2.67 - 3.69) 
2005-2006 1.77 (1.64 - 1.91) 
2007-2008 1.25 (1.17 - 1.32) 
2009-2010 1.00 
Note: HR=hazard ratio; 95% CI=95% Confidence Interval; † Includes the year of starting cART and 
patients’ age, gender, marriage status, HIV exposure category, CD4 cell counts at enrollment, 
hemoglobin level, counts of baseline symptoms, area of residence, health care setting and initial 
regimens but excludes initial regimens. ‡ Includes all factors plus initial regimens. 
 
 56 
Figure 4.1 Cumulative probability of attrition among HIV-infected patients who initiated combination 
antiretroviral therapy in the China National Free Antiretroviral Treatment Program, 2003 - 2010 
  
 
No. at risk 67732 49064 28442 15403 7247 3006 
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Figure 4.2 Cumulative probability of attrition among HIV-infected patients who initiated combination 
antiretroviral therapy in the China National Free Antiretroviral Treatment Program, 2003-2010 by 
HIV exposure group 
Note: blood = blood transfusion/former plasma donation; IDU = injection drug use; MSM= men who 
have sex with men. 
 
 
 
 
 
 
 
No. at risk       
IDU 13735 9447 5185 2490 1039 315 
Heterosexual 32194 23061 12545 6189 2581 858 
Blood 14555 11415 8011 5306 2982 1599 
MSM 2826 1992 776 297 121 45 
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Figure 4.3 Cumulative probability of attrition among HIV-infected patients who initiated combination 
antiretroviral therapy in the China National Free Antiretroviral Treatment Program, 2003-2010 by 
CD4 counts 
 
 
  
 
No. at risk       
≥350 1760 1308 771 409 185 64 
200-349 17465 12961 6524 2953 1131 449 
50-199 26648 20058 11946 6555 3044 1136 
0-49 17692 11953 7226 4052 1902 668 
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Figure 4.4 Cumulative probability of attrition among HIV-infected patients who initiated combination 
antiretroviral therapy in the China National Free Antiretroviral Treatment Program, 2003-2010 by 
calendar year of therapy initiation 
 
 
 
  
 
No. at risk       
2003-2004 2182 1687 1424 1285 1202 1135 
2005-2006 9880 7749 6819 6314 6023 1871 
2007-2008 27149 22490 20199 7804 22 0 
2009-2010 28521 17138 0    
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Figure 4.5 Cumulative probability of attrition among HIV-infected patients who initiated combination 
antiretroviral therapy in the China National Free Antiretroviral Treatment Program, 2003-2010 by 
type of initial regimen.  
Note: NVP= nevirapine; 3TC=lamivudine; AZT= zidovudine; D4T=stavudine; DDI=didanosine; 
EFV=efavirenz 
 
 
 
 
 
 
No. at risk       
Other regimens 2198 1448 941 634 495 392 
NVP+DDI+AZT/D4T 4527 3526 2743 1994 1389 925 
NVP+3TC+AZT/D4T 47515 34937 20060 10658 4484 1380 
EFV+3TC+AZT/D4T 13492 9153 4698 2117 879 309 
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V. DECREASING EXCESS MORTALITY OF HIV-INFECTED PATIENTS 
INITIATING ANTIRETROVIRAL THERAPY: COMPARISON WITH MORTALITY 
IN GENERAL POPULATION IN CHINA, 2003-2009 
 
Introduction 
Combination antiretroviral therapy (cART) provision enables human 
immunodeficiency virus (HIV)-infected patients to suppress HIV replication [156-158], 
leading to substantially lower morbidity and mortality in both resource rich and poor areas of 
the world [17, 159]. A number of prior studies have observed notable reductions in mortality 
across calendar time with increasing uptake of more efficacious cART [75, 86, 160]. 
However, mortality among HIV-infected patients remains higher in resource poor areas even 
where cART is available [18].  
Reductions in mortality from HIV-infection have also been narrowing the gap in life 
expectancy comparing HIV-infected patients to the general population [116, 119, 161, 162]. 
Among some HIV-infected patients life expectancy may approach that observed in the 
general population [117, 163]. For example, among West and South African patients 
participating in the International epidemiological Databases to Evaluate AIDS project who 
initiated cART at higher CD4 counts life expectancy estimates approach those of HIV-
uninfected individuals [115]. Mortality and life expectancy contrasts comparing HIV-
infected patients receiving cART to the general population assess the effectiveness of 
provided HIV therapy at a population level. These types of analyses also provide data for 
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policy makers for assessing future needs of HIV-infected patients and in planning allocation 
of health care and other resources. 
The Joint United Nations Programme on HIV/AIDS estimated that as of 2009, 
740,000 (range 540,000-1,000,000) adults and children were living with HIV in China [145]. 
Since 2002, HIV-infected patients in China have had access to free cART through the 
National Free Antiretroviral Treatment Program (NFATP) [137], and as of 2009 over 80,000 
patients received cART through this program [53]. As elsewhere around the world, HIV-
infected patients receiving cART experience notable reductions in morbidity and mortality in 
China [53, 148, 164]. Although NFATP only launched the national free cART program in the 
last decade, notable decreases in mortality across calendar time have already been reported 
[139]. However, this prior work has concentrated on internal comparisons of mortality 
among HIV-infected patients over time. In the present study we compare mortality estimates 
between HIV-infected patients receiving cART through NFATP with the general Chinese 
population from 2003 and 2009. We estimated both excess mortality and standardized 
mortality ratios over calendar time and evaluated risk factors for excess mortality.  
 
Methods 
Study population 
Patients receiving free cART through NFATP between 1 January 2003 and 31 
December 2009 were included [134, 137, 149]. Patients were cART eligible if they had a 
CD4 count below 200 cells/ μL (increased to 350 cells/ μL in 2008), a total lymphocyte 
counts <1200 cells/ μL or a World Health Organization stage III or IV clinical condition 
[135]. Standardized paper-based case report forms were completed by local health workers. 
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Information included demographic data, HIV exposure route, clinical symptoms and signs, 
cART administered and laboratory test results. Subsequent follow up visits occurred at 2, 4, 8 
and 12 weeks following cART initiation, and then every 3 months thereafter. We excluded 
patients who did not have information on area of residence (n=10,669) and who did not have 
any follow-up visit information before 15 December 2009 (n=714). This study was approved 
by the Institutional Review Board at the University of North Carolina at Chapel Hill. 
 
Measurements 
Factors measured at the first visit included age, sex, HIV exposure route, initial cART 
regimen, CD4 cell count, type of health care setting and area of residence (rural vs. urban). 
Antiretroviral therapy regimens were categorized as: neviripine (NVP) with lamivudine 
(3TC) and either zidovudine (AZT) or stavudine (d4T); efavirenz (EFV) with 3TC and either 
AZT or D4T; NVP and didanosine (DDI) and either AZT or D4T; and all other regimens. 
HIV exposure route included infection through blood transfusion/ former plasma donation, 
sexual transmission and injection drug use (IDU). Information on death, including reason and 
date of death, was available through the NFATP treatment withdrawal forms. These forms 
were also completed by local health workers and sent to central NFATP offices by DataFax 
(Clinical DataFax Systems, Hamilton, Ontario, Canada). Forms were completed on all 
patients known to have died at the local level through passive surveillance. Mortality data for 
the general Chinese population was obtained from China Health Statistic Year Book 2004 to 
2010. These national death statistics are based on a passive surveillance system, i.e. the 
Ministry of Health-vital registration system, to report death cases to a central national 
repository [165].  
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Statistical analysis  
Person-time was calculated from the date when patients initiated cART to the date of 
death or date of censoring. Patients were censored either at the date of withdrawal from 
NFATP or 31 December 2009, whichever occurred first. The reason for withdrawal included 
loss to follow up, treatment interruption or transferring to another health care facility. Loss to 
follow-up was defined as missing more than 3 visits and we used the latest date seen in clinic 
as the date of withdrawal. 
Observed mortality rates were calculated as number of deaths divided by person-year 
at risk and corresponding 95% confidence intervals (95% CIs) were calculated based on 
Poisson distribution [166]. Expected number of deaths was estimated by applying the 
probability of death in the general Chinese population to the study population in each 
calendar year. Patients were matched to the general population on age (by 5 year age group), 
sex, area of residence (urban versus rural) and calendar year.  
Excess mortality rates were calculated as the difference between observed deaths in 
the study population and that expected based on estimates from the general population. 
Standardized mortality ratios (SMR) were calculated as the ratio of the observed number of 
deaths in the study population to that expected from estimates based on the general 
population. As measures of precision we calculated 95% CIs for both excess mortality rates 
and standardized mortality ratios [166]. Excess mortality rates and standardized mortality 
ratios were estimated within strata defined by calendar year interval (2003-2004, 2005-2007 
and 2008-2009). This categorization was chosen to: minimize heterogeneity within groups; 
correspond with major therapeutic changes across calendar time; and preserve adequate 
sample sizes within strata. Further stratification of estimates was done according to patients’ 
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age, sex, HIV exposure route, CD4 count at cART initiation, area of residence, type of health 
care settings and type of first cART regimen received. 
We further evaluated changes in excess mortality across calendar time in 
multivariable Poisson regression models [111]. In this relative survival model, the observed 
number of deaths in each patient stratum was modeled with a Poisson process and we used 
the expected number of deaths in each stratum as an offset. Time was categorized into one 
year increments from cART initiation, assuming a piecewise constant hazard within each 
year after starting cART. Excess hazard ratios (eHRs) and associated 95% CIs were obtained 
as the antilog of the coefficient from this relative survival model. We examined changes in 
relative survival across calendar time adjusting for age, sex, HIV-exposure category, CD4 
count, initial cART regimen, type of health care setting and area of residence. In this case the 
interpretation of eHR comparing calendar years is similar to other survival models, such that 
the index group of patients experiences an instantaneous risk of death “X” times the risk 
among patients in the reference group, accounting for expected background mortality and the 
other patient characteristics included in the model. In all analyses hypothesis testing was 2-
sided and an alpha of 0.05 was used to indicate a statistically significant difference. All 
analyses were done using SAS version 9.2 (SAS Institute, Cary NC, USA).   
 
Results 
Overall 64,836 HIV-infected patients with known area of residence initiated cART in 
the Chinese NFATP between 2003 and 2009 and were included in this analysis. The 
proportion of patients receiving treatment scaled up over the years and almost half of patients 
initiated cART during 2008 and 2009 (47%) (Table 5.1). The median age at cART initiation 
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was 38 years [interquartile range (IQR): 33 - 46], 40% of patients were women, and 70% 
lived in rural areas. Across time patients appeared younger at cART initiation, were more 
likely to be men, and more likely to live in urban areas. In 2003 and 2004 nearly all patients 
were infected through blood transfusion/former plasma donation (95%), and this decreased to 
18% by 2008 and 2009.  
The median CD4 count at cART initiation decreased across time from 223 cells/mL 
in 2003/2004 to 141 cells/mL in 2008/2009. Although NVP remained the most common 
anchor agent provided across time, the use of 3TC replaced DDI in 2005/2006. Specifically 
in 2003/2004 patients predominantly received NVP and DDI with either AZT or D4T (89%), 
in comparison in 2008/2009 the most common first cART regimen was NVP and 3TC with 
either AZT or D4T (73%).  
Patients were followed on average for a median of 1.5 years (IQR: 0.5 - 3.4), 
contributing a total of 135,509 person-years of follow-up (Table 5.2). Overall 13% of 
patients were known to have died (n=8,577), with an observed mortality rate of 6.3 
deaths/100 person-years (95% CI: 6.2 - 6.4). The crude observed mortality rate decreased 
across calendar time from 9.5 to 5.6 deaths /100 person-years from 2003/2004 to 2008/2009.  
 The overall excess mortality rate was 6.0 deaths/100 person-years (95% CI: 5.9, 6.1). 
Excess mortality fell from 9.1 deaths/100 person-years (95% CI: 8.5, 9.8) in 2003/2004 to 
5.2 deaths/100 person-years (95% CI: 5.0, 5.4) in 2008/2009 (Table 5.2). The reductions in 
excess mortality rates across calendar time were evident within all strata of patient 
characteristics, including age, sex, CD4 count at cART initiation and type of initial cART 
(Table 5.3). In unadjusted analyses excess mortality rates were higher among older patients 
in each stratum of calendar years, although younger patients in 2003/2004 also had high 
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excess mortality (Figure 5.1). After adjustment for other patient characteristics, including 
age, sex, HIV exposure route, CD4 count, number of baseline symptoms, initial cART 
regimen, area of residence, and health care setting, the adjusted excess mortality rates were 
higher in older patients across all calendar periods (Figure 5.3). The most dramatic 
reductions in unadjusted excess mortality rates across calendar time occurred among patients 
with low CD4 counts at cART initiation (Figure 5.2) and comparable results were obtained in 
the adjusted analyses (Figure 5.4).   
The overall SMR was 20.1 (95% CI: 19.7, 20.5). The SMR decreased from 30.8 (95% 
CI: 28.6, 33.1) to 17.0 (95% CI: 16.5, 17.6) from 2003/2004 to 2008/2009 (Table 5.2). In 
general SMR results stratified by patient characteristic were comparable to results observed 
for excess mortality rates (Table 4, Figure 5.5). As observed with excess mortality rates, the 
reduction in SMR across calendar time was most dramatic among patients initiating cART at 
low CD4 counts. Among patients with CD4 counts below 50 cells/ μL the SMR declined 
from 103.6 (95% CI: 86.2, 124.5) to 32.2 (95% CI: 30.5, 34.0) from 2003/2004 to 
2008/2009.  
The adjusted excess mortality rate decreased from 2003/2004 to 2008/2009, with an 
eHR of 1.27 (95% CI: 1.11, 1.45), indicating the risk of death was nearly 30% higher in 
2003/2004 than 2007/2008, adjusting for background mortality and other patient 
characteristics including age, sex, HIV exposure route, area of residence, health care setting, 
CD4 count, number of baseline symptoms, and initial cART regimen (Table 5.5). Patients 
who were older at cART initiation were at a greater risk of dying with an eHR of 1.63 (95% 
CI: 1.47, 1.82) comparing patients more than 45 years of age to those less than 30. Men, 
patients living in rural areas, and those exposed to HIV through IDU were also at higher risk 
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of death. Patients who received care at larger and centralized medical care facilities appeared 
to be at lower risk than those who received care at smaller local centers. Excess mortality 
decreased with increasing CD4 counts at cART initiation, with patients who started cART 
with CD4 counts less than 50 cells/ μL at almost 10 times the risk of death compared to 
patients with CD4 counts greater than 350 cells/ μL (eHR=9.92; 95% CI, 8.59 - 11.44).  
 
Discussion 
In this study including over 64,000 HIV-infected patients initiating cART in China, 
we found both observed and excess mortality rates decreased more than 30% from 2003 to 
2009. Mortality ratios standardized to the general Chinese population also decreased by over 
30% from 2003 to 2009. The decreases in excess mortality rates and SMRs across calendar 
time were relatively consistently observed within all patient demographic and clinical 
characteristics, and after adjusting for a number of factors including age, CD4 count and 
cART regimen at therapy initiation, excess mortality decreased by over 20% from 2003/2004 
to 2008/2009. These findings are consistent with prior studies which have reported 
reductions in observed and expected mortality rates and SMRs across calendar time among 
patients initiating cART in both resource rich and poor areas of the world [100, 114, 115, 
163, 167]. 
The observed mortality rate in this study population (6 deaths/100 person-years) was 
higher in comparison to results from resource wealthy areas of the world (1 death/100 
person-years) [167], but lower than that observed in Sub-Saharan Africa (8 deaths/100 
person-years) [115]. The overall excess mortality we observed was similar to estimates from 
Sub-Saharan Africa (6 vs. 7 deaths/100 person-years, respectively), as were the SMRs (20 
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and 19, respectively) [115], but higher than reported in Europe and North America (excess 
mortality rate = 2 deaths/100 person-years [114] and SMR= 3 [167])  
Notwithstanding the substantial decreases in mortality rates across calendar time, 
HIV-infected patients in this study population consistently had greater excess mortality in 
comparison to the general Chinese population. However there were notable differences in 
excess mortality rates among groups of patients defined by demographic and clinical 
characteristics. Among some groups of patient’s mortality was less than 10 times the general 
population whereas among other groups this rose to over 100 times. The greatest differences 
in mortality were observed within CD4 count and age strata. The lowest excess mortality 
rates were among patients initiating cART at CD4 counts greater than 350 cells/ μL. This 
group of patients had less than 10 times the mortality of the general population in all calendar 
years. In comparison the highest excess mortality rates were observed among patients 
initiating cART with CD4 counts less than 50 cells/ μL. This group of patients had over 30 
times the mortality of the general population even in the most recent calendar years. In 
adjusted analyses patients starting cART with CD4 counts less than 50 cells/ μL had nearly a 
10-fold higher excess mortality compared to patients initiating cART at CD4 counts greater 
than 350 cells/ μL. These findings have been consistently reported from all areas of the world 
[115, 161] and underscore recent recommendations that cART be initiated at higher CD4 
counts to optimize overall survival [104] and that additional efforts are needed for earlier 
HIV diagnosis and treatment initiation among many HIV-infected patients [168]. 
Overall excess mortality rates increased with increasing age. In multivariable 
analyses adjusting for CD4 count and other patient characteristics patients at least 45 years of 
age had over 1.6 times excess mortality in comparison to patients less than 30 years of age. 
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Other independent factors associated with excess mortality in multivariable analyses included 
being a male, patients infected through IDU in comparison to sexual transmission, patients 
residing in rural versus urban areas, and patients receiving HIV care at local health care 
centers in comparison to larger centralized hospital settings. Prior studies have also reported 
older age, male sex, and IDU as risk factors for excess mortality [18, 100, 114]. 
It is possible that the HIV-infected patients in this study population were different 
from the general population in other characteristics that we were not able to account for (age, 
sex, area of residence and calendar year) [162]. In other words, HIV-infected patients in 
China may be at greater risk of death than the general population for reasons other than HIV, 
such as a higher prevalence of other comorbidities (e.g., Hepatitis B or C infection). Death 
ascertainment relied on reports to HIV care providers, rather than links with centralized death 
registries, therefore we may be underestimating the true mortality rates. We were also unable 
to account for duration of HIV-infection, or virologic or immunologic response to cART. 
Observed mortality rates, excess rates and standardized mortality ratios would likely be 
lower among patients with better response to cART.  
In summary, among HIV-infected patients receiving cART through the Chinese 
NFATP we have observed substantial decreases in excess mortality in comparison to the 
general Chinese population from 2003 to 2009. Further reductions will likely be achieved as 
NFATP is able to provide more efficacious first and second line cART regimens. Our results 
indicate that further reductions in mortality will follow if patients are identified earlier after 
HIV-infection and are successfully linked with HIV care. 
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Table 5.1 Characteristics of 64,836 HIV-infected patients at combination antiretroviral therapy initiation, the China National Free Antiretroviral 
Treatment Program 2003 - 2009 
 
Characteristic† 2003-2004 2005-2007 2008-2009 Total 
Total   11,366 (18%) 22,755 (35%) 30,715 (47%)    64,836 (100%) 
Age (years) 
        Median             41 (36 - 48 )            38 (32 - 45)              38 (32 - 45) 
 
             38 (33 - 46) 
    18-29 507 (5%) 3,191 (14%)   5,307 (17%)   9,005 (14%) 
    30-44 6,722 (59%)      13,548 (60%) 16,979 (55%) 37,249 (57%) 
    ≥45 4,137 (36%)  6,016 (26%)    8,429 (28%) 18,582 (29%) 
Sex *     
    Men 5,620 (49%) 13,497 (59%) 19,578 (64%) 38,695 (60%) 
    Women 5,746 (51%)  9,255 (41%) 11,136 (36%) 26,137 (40%) 
HIV exposure*     
     Blood transfusion/former plasma donation      10,787 (95%)      10,133 (47%)   5,114 (18%) 26,034 (42%) 
     Intravenous drug use   51 (1%)  3,667 (17%)   6,130 (21%)   9,848 (16%) 
     Sexual transmission 470 (4%)  7,652 (36%) 17,578 (61%) 25,700 (42%) 
Area of residence     
     Urban 469 (4%) 6,746 (30%) 12,531 (41%) 19,746 (30%) 
     Rural     10,897 (96%)      16,009 (70%) 18,184 (59%) 45,090 (70%) 
Health care setting*     
     General hospital 189 (2%) 6,344 (28%)       13,360 (44%) 19,893 (31%) 
     Infectious diseases hospital 234 (2%) 2,915 (13%)  5,304 (18%)   8,453 (13%) 
     Centers for diseases control clinic 873 (8%) 4,211 (19%)  6,551 (21%) 11,635 (18%) 
     Health care township level/prison hospital     10,042 (88%) 9,169 (40%)  5,270 (17%) 24,481 (38%) 
CD4 count (cells/ μL)*     
         Median          223 (120 - 361)          132 (45 - 217)          141 (46 - 230)           147 (51 - 240) 
         0-49   869 (11%) 5,552 (27%) 7,753 (26%) 14,174 (24%) 
         50-199 2,466 (32%) 9,082 (44%)      12,107 (41%) 23,655 (41%) 
         200-349 2,320 (30%) 4,724 (23%) 8,993 (30%) 16,037 (28%) 
         ≥350 2,086 (27%)        1,411 (7%)           816 (3%) 4,313 (7%) 
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Table 5.1 Characteristics of 64,836 HIV-infected patients at combination antiretroviral therapy initiation, the China National Free Antiretroviral 
Treatment Program 2003 - 2009 (continued) 
 
Characteristic† 2003-2004 2005-2007 2008-2009 Total 
Number of baseline symptom      
        0 1,313 (12%) 5,211 (23%) 11,855 (39%) 18,379 (28%) 
        1 1,097 (10%) 2,772 (12%) 4,271 (14%)   8,140 (13%) 
        2-3 3,116 (27%) 5,859 (26%) 6,763 (22%) 15,738 (24%) 
        ≥4 5,840 (51%) 8,913 (39%) 7,826 (25%) 22,579 (35%) 
Initiation regimen‡     
      NVP+3TC+AZT  292 (2%) 2,958 (13%)      12,699 (41%) 15,949 (25%) 
      NVP+3TC+D4T  389 (3%)      11,897 (52%) 9,723 (32%) 22,009 (34%) 
      NVP+DDI+AZT 8,326 (73%) 4,027 (18%) 807 (3%) 13,160 (20%) 
      NVP+DDI+D4T 1,799 (16%) 916 (4%) 234 (1%) 2,949 (5%) 
      EFV+3TC+AZT    75 (1%) 897 (4%)       3,665 (12%) 4,637 (7%) 
      EFV+3TC+D4T   72 (1%)       1,534 (7%)       2,952 (9%) 4,558 (7%) 
      Other regimens 413 (4%) 526 (2%) 635 (2%) 1,574 (2%) 
†Data are median (IQR) or number (%) unless otherwise stated;  
* Missing values: Sex (n=4), HIV exposure (n=3,254), Health care setting (n=374), CD4 cell count (n=6,657) 
‡ NVP= nevirapine; 3TC=lamivudine; AZT= zidovudine; d4T=stavudine; DDI=didanosine; EFV=efavirenz. 
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Table 5.2 Observed and excess mortality rates, and standardized mortality ratios, among 64,836 HIV-infected patients initiating combination 
antiretroviral therapy in the China National Free Antiretroviral Treatment Program from 2003 - 2009 
 
Mortality 2003-2004 2005-2007 2008-2009 Total 
Observed death 733 3,815 4,029 8,577 
Expected death 23.8 166.4 236.6 426.8 
Person year at follow up 7,754 55,336 72,419 135,509 
Observed mortality rate (95% CI)† 
(per 100 person-years) 
9.5 (8.8 - 10.2) 6.9 (6.7 - 7.1) 5.6 (5.4 - 5.8) 6.3 (6.2 - 6.4) 
Excess mortality rate (95% CI)‡ 
(per 100 person-years) 
9.1 (8.5 - 9.8) 6.6 (6.4 - 6.8) 5.2 (5.0 - 5.4) 6.0 (5.9 - 6.1) 
Standardized mortality ratio (95% CI)* 30.8 (28.6 - 33.1) 22.9 (22.2 - 23.7) 17.0 (16.5 - 17.6) 20.1 (19.7 - 20.5) 
† Calculated as 100× (observed death/person years at follow up)   
‡ Calculated as 100× [(observed death-expected death)/person years at follow up)] 
* Calculated as 100× (observed death/ expected death) 
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Table 5.3 Excess mortality rates among 64,836 HIV-infected patients initiating combination antiretroviral therapy stratified by patient 
characteristics, the China National Free Antiretroviral Treatment Program 2003 - 2009† 
 
Characteristic 2003-2004 2005-2007 2008-2009 
Age    
    18-29 11.0 (8.0 - 15.1) 5.9 (5.2 - 6.7) 3.3 (3.0 - 3.7) 
    30-44   9.2 (8.4 - 10.1) 6.1 (5.8 - 6.4) 5.1 (4.9 - 5.3) 
    ≥45   8.8 (7.8 - 10.0) 7.7 (7.3 - 8.1) 6.5 (6.2 - 6.9) 
Gender    
    Men   11.3 (10.3 - 12.4) 7.9 (7.6 - 8.2) 6.1 (5.9 - 6.3) 
    Women 7.2 (6.4 - 8.1) 5.2 (4.9 - 5.5) 4.1 (3.9 - 4.3) 
HIV exposure    
     Blood transfusion/former plasma donation  9.1 (8.4 - 9.8) 6.7 (6.5 - 7.0) 5.5 (5.3 - 5.8) 
     Intravenous drug use N/A‡ 6.0 (5.2 - 6.9) 7.3 (6.8 - 7.9) 
     Sexual transmission  8.6 (5.3 - 13.8) 6.4 (5.9 - 7.0) 4.0 (3.8 - 4.3) 
Area of residence    
     Rural 9.1 (8.4 - 9.8) 6.6 (6.4 - 6.8) 5.6 (5.4 - 5.8) 
     Urban 10.9 (7.1 - 16.7) 6.4 (5.9 - 7.0) 4.3 (4.0 - 4.6) 
Health care setting    
     General hospital   19.1 (11.5 - 31.7) 6.5 (5.9 - 7.2) 5.2 (4.9 - 5.5) 
     Infectious diseases hospital   5.0 (2.4 - 10.5) 4.6 (4.0 - 5.4) 2.4 (2.1 - 2.7) 
     Centers for diseases control clinic   13.5 (10.7 - 17.1) 7.4 (6.8 - 8.1) 6.1 (5.7 - 6.5) 
     Health care under township level/prison hospital        8.8 (8.1 - 9.5) 6.6 (6.3 - 6.9) 5.7 (5.4 - 6.0) 
CD4  count (cells/ μL)    
         0-49   27.8 (23.1 - 33.4)   15.5 (14.6 - 16.4) 9.1 (8.6 - 9.6) 
         50-199 7.8 (6.4 - 9.4) 5.9 (5.5 - 6.3) 4.9 (4.6 - 5.2) 
         200-349 1.2 (0.7 - 1.9) 2.5 (2.2 - 2.8) 2.7 (2.5 - 3.0) 
         ≥350 1.9 (1.3 - 2.8) 1.4 (1.2 - 1.7) 2.1 (1.8 - 2.5) 
Number of baseline symptom     
        0   8.0 (6.3 - 10.1) 2.9 (2.6 - 3.3) 2.6 (2.4 - 2.8) 
        1 5.6 (4.2 - 7.5) 4.8 (4.3 - 5.4) 4.5 (4.1 - 5.0) 
        2-3 6.3 (5.4 - 7.4) 6.4 (6.0 - 6.8) 5.6 (5.3 - 6.0) 
        ≥4   12.1 (11.0 - 13.3) 8.5 (8.1 - 8.9) 7.1 (6.8 - 7.4) 
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Table 5.3 Excess mortality rates among 64,836 HIV-infected patients initiating combination antiretroviral therapy stratified by patient 
characteristics, the China National Free Antiretroviral Treatment Program 2003 - 2009† (continued) 
 
Characteristic 2003-2004 2005-2007 2008-2009 
Initiation regimen*    
      NVP+3TC+AZT   5.2 (2.3 - 11.6) 5.7 (5.0 - 6.5) 4.7 (4.4 - 5.1) 
      NVP+3TC+D4T 0.8 (0.2 - 3.2) 7.6 (7.2 - 8.1) 4.9 (4.6 - 5.2) 
      NVP+DDI+AZT   10.8 (10.0 - 11.7) 6.8 (6.5 - 7.1) 6.0 (5.6 - 6.4) 
      NVP+DDI+D4T        6.5 (5.4 - 7.9) 4.8 (4.3 - 5.4) 4.0 (3.4 - 4.7) 
      EFV+3TC+AZT N/A‡ 2.9 (2.1 - 4.1) 4.8 (4.2 - 5.5) 
      EFV+3TC+D4T N/A‡ 7.5 (6.2 - 9.0) 6.7 (6.0 - 7.5) 
      Other regimens 4.8 (3.0 - 7.6) 4.8 (3.9 - 5.9) 7.1 (6.0 - 8.5) 
                      †. All of excess mortality rates were per 100 person-years 
                      ‡N/A: excess mortality rates were not estimated within strata with fewer than 100 patients.  
                      * NVP= nevirapine; 3TC=lamivudine; AZT= zidovudine; d4T=stavudine; DDI=didanosine; EFV=efavirenz. 
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Table 5.4 Standardized mortality ratios among 64,836 HIV-infected patients initiating combination antiretroviral therapy stratified by patient 
characteristics, the China National Free Antiretroviral Treatment Program 2003 – 2009 
 
Characteristic 2003-2004 2005-2007 2008-2009 
Age    
    18-29 N/A*   114.9 (102.0 - 129.5) 70.8 (63.5 - 79.0) 
    30-44 54.1 (49.2 - 59.4) 37.8 (36.2 - 39.4) 31.6 (30.4 - 33.0) 
    ≥45 16.8 (14.9 - 18.9) 13.4 (12.7 - 14.1)       9.1 (8.6 - 9.6) 
Gender    
    Men 30.9 (28.1 - 33.9) 21.9 (21.0 - 22.8) 15.6 (15.0 - 16.2) 
    Women 30.7 (27.4 - 34.3) 24.9 (23.7 - 26.2) 20.7 (19.6 - 21.8) 
HIV exposure    
     Blood transfusion/former plasma donation  30.7 (28.6 - 33.1) 22.5 (21.7 - 23.3) 16.2 (15.5 - 16.9) 
     Intravenous drug use N/A* 47.6 (41.5 - 54.5) 53.9 (50.1 - 57.9) 
     Sexual transmission 28.2 (17.8 - 44.7) 22.6 (20.8 - 24.5) 13.3 (12.5 - 14.1) 
Area of residence    
     Rural 30.6 (28.5 - 33.0) 22.5 (21.7 - 23.3) 16.9 (16.3 - 17.5) 
     Urban 37.1 (24.4 - 56.3) 26.4 (24.2 - 28.7) 17.4 (16.4 - 18.6) 
Health care setting    
     General hospital N/A* 29.0 (26.3 - 31.9) 19.8 (18.5 - 20.9) 
     Infectious diseases hospital N/A* 16.4 (14.1 - 19.1) 9.0 (7.9 - 10.2) 
     Centers for diseases control clinic 56.7 (44.9 - 71.7) 28.8 (26.4 - 31.4) 20.9 (19.5 - 22.4) 
     Health care under township level/prison hospital 29.3 (27.1 - 31.7) 21.9 (21.1 - 22.7) 16.3 (15.6 - 17.1) 
CD4 cell count (cells/ μL)    
         0-49 103.6 (86.2 - 124.5) 61.3 (57.8 - 64.9) 32.2 (30.5 - 34.0) 
         50-199 25.0 (20.8 - 30.2) 20.0 (18.8 - 21.2) 15.4 (14.6 - 16.3) 
         200-349       4.8 (3.1 - 7.2) 9.4 (8.5 - 10.4) 9.7 (8.8 - 10.5) 
         ≥350 7.1 (5.0 - 10.2) 5.6 (4.8 - 6.6)       6.7 (5.7 - 7.9) 
Number of baseline symptom     
        0 32.0 (25.5 - 40.2) 11.9 (10.6 - 13.4)     10.2 (9.4 - 11.1) 
        1 20.6 (15.5 - 27.3) 17.8 (15.9 - 19.9) 15.1 (13.8 - 16.6) 
        2-3 21.0 (18.0 - 24.6) 21.8 (20.5 - 23.2) 17.1 (16.1 - 18.2) 
        ≥4 38.8 (35.4 - 42.6) 28.0 (26.8 - 29.2) 21.5 (20.6 - 22.5) 
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Table 5.4 Standardized mortality ratios among 64,836 HIV-infected patients initiating combination antiretroviral therapy stratified by patient 
characteristics, the China National Free Antiretroviral Treatment Program 2003 – 2009 (continued) 
 
Characteristic 2003-2004 2005-2007 2008-2009 
Initiation regimen†    
      NVP+3TC+AZT N/A* 24.8 (21.7 - 28.3) 17.4 (16.2 - 18.8) 
      NVP+3TC+D4T 3.4 (1.1 - 10.5) 28.3 (26.7 - 30.0) 16.5 (15.7 - 17.4) 
      NVP+DDI+AZT 35.7 (32.9 - 38.7) 22.1 (21.2 - 23.2) 16.4 (15.5 - 17.4) 
      NVP+DDI+D4T 22.7 (18.7 - 27.4) 16.6 (14.9 - 18.6) 12.1 (10.5 - 14.0) 
      EFV+3TC+AZT N/A*     12.2 (8.8 - 16.9) 20.5 (17.9 - 23.5) 
      EFV+3TC+D4T N/A* 25.6 (21.4 - 30.6) 21.5 (19.3 - 23.9) 
      Other regimens 18.9 (12.1 - 29.6) 19.0 (15.4 - 23.3) 23.8 (20.1 - 28.3) 
* N/A: Standardized mortality ratios were not estimated within strata with expected deaths fewer than 0.5 patients. 
† NVP= nevirapine; 3TC=lamivudine; AZT= zidovudine; d4T=stavudine; DDI=didanosine; EFV=efavirenz. 
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Table 5.5 Adjusted excess hazard ratios among 64,836 HIV-infected patients initiating combination 
antiretroviral therapy, the China National Free Antiretroviral Treatment Program 2003 – 2009† 
 
 eHR (95% CI) 
Calendar period of follow up  
        2003-2004 1.27 (1.11 - 1.45) 
        2005-2007 1.16 (1.09 - 1.23) 
        2008-2009 1.00 
Age (years)  
    ≥45 1.63 (1.47 - 1.82) 
    30-44 1.27 (1.15 - 1.40) 
    18-29 1.00 
Gender  
    Men 1.37 (1.29 - 1.45) 
    Women 1.00 
HIV exposure  
     Blood transfusion/former plasma donation  0.98 (0.89 - 1.08) 
     Intravenous drug use 1.72 (1.57 - 1.88) 
     Sexual transmission 1.00 
Area of residence  
      Rural 1.17 (1.08 - 1.26) 
      Urban 1.00 
Health care setting  
     General hospital 0.85 (0.76 - 0.95) 
     Infectious diseases hospital 0.34 (0.30 - 0.40) 
     Centers for diseases control clinic 0.89 (0.81 - 0.97) 
     Health care under township level/prison hospital 1.00 
CD4  count (cells/ μL)  
         0-49  9.92 (8.59 - 11.44) 
         50-199 4.08 (3.55 - 4.70) 
         200-349 1.82 (1.56 - 2.11) 
         ≥350 1.00 
Number of baseline symptom   
        ≥4 2.10 (1.91 - 2.31) 
        2-3 1.65 (1.49 - 1.82) 
        1 1.35 (1.19 - 1.52) 
        0 1.00 
Initiation regimen‡  
      NVP+3TC+AZT 1.11 (0.94 - 1.31) 
      NVP+3TC+D4T 1.09 (0.93 - 1.27) 
      NVP+DDI+AZT 1.37 (1.17 - 1.62) 
      NVP+DDI+D4T 0.97 (0.80 - 1.17) 
      Other regimens 1.24 (1.00 - 1.54) 
      EFV+3TC+D4T 1.20 (1.00 - 1.43) 
      EFV+3TC+AZT 1.00 
†Estimates from one model including all characteristics listed in table 
‡ NVP= nevirapine; 3TC=lamivudine; AZT= zidovudine; d4T=stavudine; DDI=didanosine; 
EFV=efavirenz. 
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Figure 5.1 Excess mortality rates by calendar year interval among 64,836 HIV-infected patients 
initiating combination antiretroviral therapy in the China National Free Antiretroviral Treatment 
Program 2003 – 2009 by age at therapy initiation. 
 
 
 
 
No.           
2003/2004 76 582 2156 3483 2950 2325 1943 726 238 95 
2005/2007 1361 5110 12028 16002 13490 8500 7485 3379 1379 873 
2008/2009 3346 10237 18527 21530 16800 10194 7863 4674 2401 2138 
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Figure 5.2 Excess mortality rates by calendar year interval among 64,836 HIV-infected patients 
initiating combination antiretroviral therapy in the China National Free Antiretroviral Treatment 
Program 2003 – 2009 by CD4 cell count at therapy initiation. 
 
 
 
 
 
 
No.         
2003/2004 994 840 1007 1088 1230 885 752 2629 
2005/2007 10821 7076 7170 8292 6780 5146 3284 9017 
2008/2009 20280 11809 11309 13419 10914 8750 5197 7207 
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Figure 5.3 Adjusted excess mortality rates by calendar year interval among 64,836 HIV-infected 
patients initiating combination antiretroviral therapy in the China National Free Antiretroviral 
Treatment Program 2003 – 2009 by age  
 
Note: NVP= nevirapine; 3TC=lamivudine; AZT= zidovudine. The adjusted excess mortality rates 
were estimated from one model including calendar year, age, sex, HIV exposure category, CD4 
count, area of residence, health care setting, number of baseline symptoms and initial antiretroviral 
therapy regimen. 
 
 
 
 
No.           
2003/2004 50 364 1284 2201 1995 1488 1306 453 169 58 
2005/2007 1139 4268 9724 12695 10708 6573 5903 2615 1067 617 
2008/2009 2925 9040 16228 18590 14339 8496 6540 3850 1964 1699 
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Figure 5.4 Adjusted excess mortality rates by calendar year interval among 64,836 HIV-infected 
patients initiating combination antiretroviral therapy in the China National Free Antiretroviral 
Treatment Program 2003 – 2009 by CD4 count at therapy initiation.  
 
 
Note: NVP= nevirapine; 3TC=lamivudine; AZT= zidovudine. The adjusted excess mortality rates 
were estimated from one model including calendar year, age, sex, HIV exposure category, CD4 
count, area of residence, health care setting, number of baseline symptoms and initial antiretroviral 
therapy regimen. 
 
 
No.         
2003/2004 348 268 263 298 272 220 183 294 
2005/2007 2200 1566 1466 1485 1107 897 513 602 
2008/2009 3295 2593 2394 2467 2058 1756 1300 906 
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Figure 5.5 Standardized mortality ratios among 64,836 HIV-infected patients initiating combination antiretroviral therapy stratified by patient 
characteristics, the China National Free Antiretroviral Treatment Program 2003-2009 † 
 
Note: NVP= nevirapine; 3TC=lamivudine; AZT= zidovudine; d4T=stavudine; DDI=didanosine; EFV=efavirenz. †Standardized mortality ratios 
are not depicted for strata with fewer than 1000 patients, including in 2003/2004: age 18-29, Intravenous drugs use, sexual transmission, urban, 
general hospital, infectious diseases hospital, centers for diseases control clinic, CD4 count 0-49 cells/ μL, NVP+3TC+AZT, NVP+3TC+D4T 
EFV+3TC+AZT, EFV+3TC+D4T and other regimens; in 2005-2007: NVP+DDI+D4T, EFV+3TC+AZT and other regimens; in 2008/2009: CD4 
count ≥350cells/ μL, NVP+DDI+AZT, NVP+DDI+D4T, and other regimens.  
* Standardized mortality ratios for 2003/2004 were: age 30-44 54.1 [95% confidence interval (CI): 49.2 - 59.4]; for 2005-2007: age18-29 114.9 
(95CI%: 102.0 - 129.5), intravenous drugs use 47.6 (95% CI: 41.5 - 54.5), CD4 count 0-49 cells/ μL 61.3 (95%CI: 57.8 - 64.9); for 2008/2009: age 
18-29 70.8 (95CI%: 63.5 - 79.0), intravenous drugs use 53.9 (95% CI: 50.1 - 57.9). 
 84 
 
 
 
 
 
 
VI. CONCLUSIONS 
 
Summary of findings  
This study is one of the largest to evaluate retention in HIV care and the only study to 
date to be carried out in China. An improved understanding of attrition and factors associated 
with risk of attrition could help direct future public health interventions to maintain retention 
in treatment and thereby improve patient clinical outcomes. Also, this study assessed changes 
of difference between the mortality of HIV-infected patients initiating cART with the 
mortality in general population across calendar time. The ability to contrast mortality rates 
among HIV-infected patients receiving cART with general Chinese mortality data allowed us 
to generate data relevant to HIV care providers and policy makers in China as they evaluate 
cART provision in China and the future allocation of health care resource. 
We observed a cumulative probability of attrition from cART initiation of 9% at 12 
months, 16% at 24 months and 24% at 60 months among 67,732 HIV-infected patients 
initiating cART. Factors associated with attrition included younger age, being male and being 
single or divorced. Patients with higher CD4 counts at cART initiation were more likely to be 
lost to HIV care. The proportion of patients remaining in HIV care increased in more recent 
calendar years and among patients who initiated more modern cART regimens. Patients who 
received HIV care at larger and more centralized health care settings were more likely to be 
lost to care than patients receiving care at village level clinics. Using different time intervals 
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to define attrition, including 180, 270 and 360 days from last observation, our results were 
consistent irrespective of the definition of attrition we applied. 
Among over 64,000 HIV-infected patients initiating cART in China we found both 
observed and excess mortality rates decreased more than 30% from 2003 to 2009. Also, the 
standardized mortality ratio decreased from 30.8 (95% CI: 28.6, 33.1) to 17.0 (95% CI: 16.5, 
17.6) from 2003/2004 to 2008/2009. The decreases in excess mortality rates and SMRs 
across calendar time were largely consistent within all patient demographic and clinical 
characteristics. In a multivariable analysis, the high risk of excess mortality was statistically 
associated with older age, male, being IDU, living in rural area, lower CD4 counts, higher 
numbers of symptoms and earlier years of staring cART 
 
Limitations 
This study has some limitations. One limitation is the lack of some covariates, 
including date of HIV infection, HIV RNA viral load at enrollment and drug resistance 
results, which may impact the effect of the main exposure and other measured confounders 
on the association of attrition in care and excess mortality. Also, we were unable to evaluate 
the effect of longitudinal CD4 counts or HIV RNA levels on retention as these data were not 
available in the early years of the NFATP program. 
Secondly, we were not able to link the study population with national death registries, 
nor was there active follow-up of patients lost to care. Thus, our estimate of attrition may be 
overestimated due to the patients who died but their death was not reported to the clinic. We 
may also be underestimating the observed mortality rates if unobserved mortality was 
substantial. Given that attrition from HIV care was greater among patients with higher CD4 
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cell counts we do not expect that mortality was strongly associated with attrition and 
censoring. 
Thirdly, our findings of attrition in care may not generalize to clinics in other areas of 
the world because the unique contextual frames of the Chinese NFATP program. For 
example, as part of NFATP all patients received free antiretroviral therapy as well as other 
needed HIV care. Findings from other settings showed that retention increases in programs 
that offer free ART. 
Finally, for the estimates of excess mortality, we were unable to match on some 
characteristics which were different from the general population such as a higher prevalence 
of other comorbidities (e.g., Hepatitis B or C infection). 
 
Implications 
This study describing attrition from HIV care provides relevant information to guide 
local physicians and health workers with respect to the best practices in monitoring treatment 
of patients receiving routine clinic care. It also supports policy makers to develop better 
strategies to control and minimize factors associated with attrition, as they may lead to 
treatment failure including drug resistance, toxicity and poor clinical response. Retention in 
HIV care is essential for optimizing individual and public health outcomes. Attrition, even 
the degree observed in our study, can lead to premature morbidity and mortality, and possibly 
affect further transmission of HIV and HIV resistant drug variants. Effective strategies to 
promote retention in HIV care programs are needed. In China intervention strategies may 
include focusing particularly on younger and male patients and those with higher CD4 counts 
at therapy initiation. 
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The results of the change in long-term excess mortality among HIV-infected patients 
receiving cART can provide information on the public health effectiveness of medical 
regimens after taking into account factors related to toxicity, drug resistance and adherence. 
Meanwhile, demonstrating the excess mortality trends can be useful for health resource 
allocation and optimization of current therapeutic regimens. Among HIV-infected patients 
receiving cART through the Chinese NFATP we have observed substantial decreases in 
excess mortality in comparison to the general population from 2003 to 2009. It is anticipated 
further reductions will be achieved as NFATP is able to provide more efficacious first and 
second line cART regimens. Our results indicate that further reductions in mortality will also 
entail identifying patients early after HIV-infection and linking then with HIV care. 
 
Future plans 
We were unable to link the study population with national death registries, such as the 
Death Cause Register System of the Chinese Ministry of Health. Future work with this 
cohort of patients would benefit from a linkage between these two systems to identify any 
deaths that may not have been captured by local health workers. It may also be beneficial to 
initiate an active tracing system among patients who are lost to HIV care. Given this is a 
labor and cost intensive type of intervention, this work may be best focused among the most 
at risk patients. It may be possible to undertake a smaller study where a random group of 
patients lost to HIV care are actively traced as has been done previously in other areas of the 
world [46]. This information can then be used to better understand the reasons for attrition 
from HIV care, including the risk of death among these patients.  
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Finally, it may also be useful to use modeling strategies to estimate the duration of 
infection among HIV-infected patients as they enter HIV care through the NFATP program 
in China. If this data can be accurately estimated then it may provide relevant information on 
delays for accessing HIV care and may be used in additional analyses evaluating HIV 
prognosis or response to therapy in this population. Finally, a high priority for future work is 
implementing routine CD4 cell count and HIV RNA level testing both at cART initiation and 
longitudinally. Although resource intensive and challenging to implement especially in rural 
and isolated areas of China, this data would likely prove invaluable to HIV care providers as 
well as future projects evaluating response to cART therapy in China.  
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Appendix A  
Additional tables 
Table A.1 Clinical and demographic characteristics associated with attrition among HIV-infected 
patients at combination antiretroviral therapy initiation, the China National Free Antiretroviral 
Treatment Program 2003 - 2010 (according to the definition of attrition as 180 days) 
 
Characteristic Unadjusted HR 
(95% CI) 
*Adjusted HR  
(95% CI) 
Age (years)   
 18-29 1.34 (1.27 - 1.41) 1.11 (1.04 - 1.18) 
 30-44 1.22 (1.18 - 1.28) 0.98 (0.93 - 1.03) 
  ≥45 1 1 
Gender   
 Male 1.18 (1.14 - 1.22) 1.06 (1.02 - 1.11) 
 Female 1 1 
Marital status   
 Divorced 1.28 (1.20 - 1.36) 1.25 (1.16 - 1.34) 
 Single 1.39 (1.33 - 1.45) 1.20 (1.13 - 1.26) 
 Widowed  0.97 (0.91 - 1.03) 1.06 (0.98 - 1.15) 
 Married  1 1 
HIV exposure   
 Blood transfusion/former plasma donation 1.08 (1.03 - 1.12) 0.84 (0.77 - 0.91) 
 Intravenous drug use  1.98 (1.90 - 2.06) 1.67 (1.59 - 1.75) 
 Homosexual transmission 0.51 (0.44 - 0.58) 0.53 (0.46 - 0.62) 
 Heterosexual transmission 1 1 
Area of residence   
 Eastern region 0.79 (0.76 - 0.82) 1.01 (0.95 - 1.09) 
 Central region 0.88 (0.83 - 0.92) 0.77 (0.71 - 0.83) 
 Western region 1 1 
Health care setting   
 General hospital 2.11 (1.87 - 2.38) 1.26 (1.06 - 1.48) 
 Infectious diseases hospital 1.56 (1.37 - 1.76) 1.00 (0.84 - 1.19) 
 Centers for diseases control clinic 1.49 (1.31 - 1.69) 1.04 (0.88 - 1.22) 
 Health care center at township level 1.88 (1.65 - 2.13) 1.37 (1.17 - 1.61) 
 Prison hospital 4.36 (3.68 - 5.15) 2.32 (1.89 - 2.86) 
 Village clinic 1 1 
CD4 cell count (cells/ μL)   
     ≥350 1.47 (1.34 - 1.61) 1.57 (1.40 - 1.76) 
     200-349 1.08 (1.03 - 1.13) 1.04 (0.99 - 1.11) 
     50-199 1.03 (0.99 - 1.08) 1.00 (0.95 - 1.05) 
     0-49 1 1 
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Table A.1 Clinical and demographic characteristics associated with attrition among HIV-infected 
patients at combination antiretroviral therapy initiation, the China National Free Antiretroviral 
Treatment Program 2003 - 2010 (according to the definition of attrition as 180 days) (continued) 
Characteristic Unadjusted HR 
 (95% CI) 
*Adjusted HR 
 (95% CI) 
Hemoglobin (g/L)   
     0-79 1.18 (1.08 - 1.29) 1.19 (1.07 - 1.31) 
     ≥80 1 1 
ALT (U/L)    
     ≥100 1.24 (1.15 - 1.35)  
     0-99 1  
Number of baseline symptom    
     ≥4 1.12 (1.08 - 1.17) 1.05 (1.00 - 1.11) 
     2-3 1.01 (0.96 - 1.05) 0.97 (0.92 - 1.03) 
     1 1.03 (0.98 - 1.09) 0.99 (0.93 - 1.05) 
     0 1 1 
Initiation cART regimen   
      NVP+3TC+AZT 0.93 (0.88 - 1.00) 0.96 (0.89 - 1.03) 
      NVP+3TC+D4T 1.05 (0.99 - 1.12) 0.94 (0.88 - 1.01) 
      NVP+DDI+AZT 1.56 (1.43 - 1.70) 1.53 (1.34 - 1.74) 
      NVP+DDI+D4T 1.86 (1.71 - 2.03) 0.96 (0.83 - 1.10) 
      EFV+3TC+AZT 1 1 
      EFV+3TC+D4T 0.96 (0.89 - 1.04) 0.89 (0.81 - 0.97) 
      Other regimens 1.55 (1.41 - 1.71) 1.31 (1.16 - 1.48) 
Year of cART initiation    
     2003-2004 3.54 (3.31 - 3.79) 4.23 (3.76 - 4.75) 
     2005-2006 2.13 (2.02 - 2.24) 2.14 (2.01 - 2.27) 
     2007-2008 1.38 (1.31 - 1.44) 1.32 (1.25 - 1.39) 
     2009-2010 1 1 
*Adjusted hazard ratios are based on one model including all characteristics listed in column except 
ALT. Note: HR = hazard ratio; 95% CI = 95% Confidence Interval; ALT=alanine aminotransferase; 
cART=Combination Antiretroviral Therapy; NVP= nevirapine; 3TC=lamivudine; AZT= zidovudine; 
D4T=stavudine; DDI=didanosine; EFV=efavirenz.  
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Table A.2 Clinical and demographic characteristics associated with attrition among HIV-infected 
patients at combination antiretroviral therapy initiation, the China National Free Antiretroviral 
Treatment Program 2003 - 2010 (according to the definition of attrition as 270 days) 
 
Characteristic Unadjusted HR 
(95% CI) 
*Adjusted HR  
(95% CI) 
Characteristic   
Age (years) 1.55 (1.45 - 1.66) 1.07 (0.98 - 1.16) 
 18-29 1.26 (1.19 - 1.33) 0.90 (0.84 - 0.97) 
 30-44 1 1 
  ≥45   
Gender 1.33 (1.27 - 1.39) 1.10 (1.04 - 1.17) 
 Male 1 1 
 Female   
Marital status 1.48 (1.37 - 1.61) 1.35 (1.24 - 1.48) 
 Divorced 1.74 (1.65 - 1.83) 1.33 (1.24 - 1.42) 
 Single 0.97 (0.89 - 1.04) 1.16 (1.05 - 1.29) 
 Widowed  1 1 
 Married    
HIV exposure 0.78 (0.73 - 0.83) 0.71 (0.63 - 0.80) 
 Blood transfusion/former plasma donation 2.26 (2.15 - 2.38) 1.92 (1.80 - 2.05) 
 Intravenous drug use  0.50 (0.41 - 0.60) 0.46 (0.37 - 0.56) 
 Homosexual transmission 1 1 
 Heterosexual transmission   
Area of residence 0.93 (0.87 - 0.99) 1.04 (0.95 - 1.13) 
 Eastern region 0.57 (0.54 - 0.60) 0.67 (0.60 - 0.74) 
 Central region 1 1 
 Western region   
Health care setting 2.70 (2.26 - 3.23) 1.12 (0.87 - 1.43) 
 General hospital 2.30 (1.91 - 2.76) 1.11 (0.86 - 1.42) 
 Infectious diseases hospital 1.68 (1.40 - 2.02) 0.97 (0.76 - 1.24) 
 Centers for diseases control clinic 1.76 (1.46 - 2.12) 1.26 (0.99 - 1.60) 
 Health care center at township level 6.56 (5.24 - 8.22) 2.27 (1.70 - 3.02) 
 Prison hospital 1 1 
 Village clinic   
CD4 cell count (cells/ μL) 1.65 (1.47 - 1.86) 1.83 (1.59 - 2.10) 
     ≥350 1.15 (1.08 - 1.22) 1.09 (1.01 - 1.17) 
     200-349 1.00 (0.94 - 1.06) 0.98 (0.91 - 1.04) 
     50-199 1 1 
     0-49   
Hemoglobin (g/L) 1.25 (1.12 - 1.40) 1.27 (1.11 - 1.44) 
     0-79 1 1 
     ≥80   
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Table A.2 Clinical and demographic characteristics associated with attrition among HIV-infected 
patients at combination antiretroviral therapy initiation, the China National Free Antiretroviral 
Treatment Program 2003 - 2010 (according to the definition of attrition as 270 days) (continued) 
 
Characteristic Unadjusted HR 
(95% CI) 
*Adjusted HR  
(95% CI) 
ALT (U/L)  1.28 (1.15 - 1.42)  
     ≥100 1  
     0-99   
Number of baseline symptom  1.04 (0.99 - 1.10)  
     ≥4 0.95 (0.89 - 1.01)  
     2-3 0.95 (0.89 - 1.02)  
     1 1  
     0   
Initiation cART regimen 0.88 (0.81 - 0.95) 0.94 (0.86 - 1.03) 
      NVP+3TC+AZT 0.84 (0.78 - 0.91) 0.82 (0.75 - 0.90) 
      NVP+3TC+D4T 1.05 (0.93 - 1.18) 1.57 (1.30 - 1.88) 
      NVP+DDI+AZT 1.14 (1.01 - 1.28) 0.97 (0.81 - 1.18) 
      NVP+DDI+D4T 1 1 
      EFV+3TC+AZT 0.87 (0.79 - 0.97) 0.83 (0.74 - 0.93) 
      EFV+3TC+D4T 1.25 (1.10 - 1.41) 1.34 (1.15 - 1.56) 
      Other regimens   
Year of cART initiation  2.11 (1.92 - 2.33) 3.04 (2.58 - 3.58) 
     2003-2004 1.51 (1.41 - 1.62) 1.54 (1.42 - 1.68) 
     2005-2006 1.26 (1.18 - 1.34) 1.22 (1.14 - 1.31) 
     2007-2008 1 1 
*Adjusted hazard ratios are based on one model including all characteristics listed in column except 
ALT. Note: HR = hazard ratio; 95% CI = 95% Confidence Interval; ALT=alanine aminotransferase; 
cART=Combination Antiretroviral Therapy; NVP= nevirapine; 3TC=lamivudine; AZT= zidovudine; 
D4T=stavudine; DDI=didanosine; EFV=efavirenz.  
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Table A.3 Clinical and demographic characteristics associated with attrition among HIV-infected 
patients at combination antiretroviral therapy initiation, the China National Free Antiretroviral 
Treatment Program 2003 - 2010 (according to the definition of attrition as 360 days) 
 
Characteristic Unadjusted HR  
(95% CI) 
*Adjusted HR  
(95% CI) 
Age (years)   
 18-29 1.63 (1.51 - 1.76) 1.03 (0.94 - 1.14) 
 30-44 1.28 (1.20 - 1.36) 0.88 (0.81 - 0.96) 
  ≥45 1 1 
Gender   
 Male 1.36 (1.29 - 1.43) 1.11 (1.03 - 1.19) 
 Female 1 1 
Marital status   
     Divorced 1.57 (1.43 - 1.72) 1.41 (1.28 - 1.57) 
 Single 1.87 (1.76 - 1.98) 1.37 (1.28 - 1.48) 
 Widowed  0.95 (0.86 - 1.05) 1.17 (1.04 - 1.32) 
 Married  1 1 
HIV exposure   
 Blood transfusion/former plasma donation 0.65 (0.61 - 0.71) 0.62 (0.54 - 0.71) 
 Intravenous drug use 2.30 (2.17 - 2.43) 1.97 (1.83 - 2.12) 
 Homosexual transmission 0.53 (0.43 - 0.65) 0.49 (0.39 - 0.62) 
 Heterosexual transmission 1 1 
Area of residence   
 Eastern region 0.93 (0.86 - 1.00) 0.98 (0.89 - 1.08) 
 Central region 0.50 (0.47 - 0.53) 0.65 (0.58 - 0.74) 
 Western region 1 1 
Health care setting   
 General hospital 4.05 (3.18 - 5.16) 1.69 (1.19 - 2.40) 
 Infectious diseases hospital 3.71 (2.90 - 4.74) 1.82 (1.28 - 2.59) 
 Centers for diseases control clinic 2.47 (1.93 - 3.16) 1.51 (1.06 - 2.13) 
 Health care center at township level 2.28 (1.77 - 2.93) 1.81 (1.28 - 2.56) 
 Prison hospital 10.71 (8.07 - 14.22) 3.80 (2.59 - 5.58) 
 Village clinic 1 1 
CD4 cell count (cells/ μL)   
     ≥350 1.73 (1.53 - 1.97) 2.07 (1.78 - 2.41) 
     200-349 1.13 (1.06 - 1.21) 1.06 (0.98 - 1.15) 
     50-199 0.94 (0.88 - 1.00) 0.93 (0.86 - 1.00) 
     0-49 1 1 
Hemoglobin (g/L)   
     0-79 1.34 (1.18 - 1.51) 1.33 (1.15 - 1.53) 
     ≥80 1 1 
ALT (U/L)    
     ≥100 1.30 (1.15 - 1.46)  
     0-99 1  
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Table A.3 Clinical and demographic characteristics associated with attrition among HIV-infected 
patients at combination antiretroviral therapy initiation, the China National Free Antiretroviral 
Treatment Program 2003 - 2010 (according to the definition of attrition as 360 days) (continued) 
 
Characteristic Unadjusted HR  
(95% CI) 
*Adjusted HR  
(95% CI) 
Number of baseline symptom    
     ≥4 1.02 (0.96 - 1.09)  
     2-3 0.94 (0.88 - 1.01)  
     1 0.94 (0.86 - 1.01)  
     0 1  
Initiation cART regimen   
      NVP+3TC+AZT 0.83 (0.76 - 0.91) 0.93 (0.84 - 1.03) 
      NVP+3TC+D4T 0.77 (0.70 - 0.84) 0.79 (0.71 - 0.87) 
      NVP+DDI+AZT 0.82 (0.71 - 0.94) 1.45 (1.17 - 1.81) 
      NVP+DDI+D4T 0.97 (0.85 - 1.11) 1.01 (0.82 - 1.25) 
      EFV+3TC+AZT 1 1 
      EFV+3TC+D4T 0.83 (0.74 - 0.93) 0.79 (0.70 - 0.90) 
      Other regimens 1.21 (1.06 - 1.39) 1.44 (1.22 - 1.70) 
Year of cART initiation    
     2003-2004 1.84 (1.64 - 2.06) 2.79 (2.32 - 3.36) 
     2005-2006 1.36 (1.25 - 1.48) 1.38 (1.25 - 1.52) 
     2007-2008 1.20 (1.11 - 1.29) 1.17 (1.08 - 1.27) 
     2009-2010 1 1 
*Adjusted hazard ratios are based on one model including all characteristics listed in column except 
ALT. Note: HR = hazard ratio; 95% CI = 95% Confidence Interval; ALT=alanine aminotransferase; 
cART=Combination Antiretroviral Therapy; NVP= nevirapine; 3TC=lamivudine; AZT= zidovudine; 
D4T=stavudine; DDI=didanosine; EFV=efavirenz.  
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Table A.4 Comparison of Characteristics HIV-infected patients at combination antiretroviral therapy 
initiation between with and without follow-up, the China National Free Antiretroviral Treatment 
Program 2003 - 2010  
 
Characteristic With Without  P value 
Age (years)    
18-29 14,280 (17%)   648 (22%)  
30-44 45,089 (55%) 1,421 (49%)  
≥45 22,558 (28%)    827 (29%) <.0001 
Gender    
Female 29,743 (36%)     839 (29%)  
Male 52,180 (64%)  2,057 (71%) <.0001 
Marital status    
Single 13,381 (16%)     600 (21%)  
Married 55,932 (68%)   1,851 (64%)  
Divorced 6,006 (7%)   262 (9%)  
Widowed 6,399 (7%)   168 (6%) <.0001 
HIV exposure    
Blood transfusion/former plasma donation 15,725 (23%)   174 (6%)  
Intravenous drug use 15,974 (22%)     736 (27%)  
Homosexual transmission 4,204 (4%)     263 (10%)  
Heterosexual transmission 40,748 (51%)  1,556 (57%) <.0001 
Area of residence    
Eastern region 10,664 (13%)    678 (23%)  
Central region 24,416 (30%)    430 (15%)  
Western region 46,847 (57%) 1,788 (62%) <.0001 
Health care setting    
General hospital 33,081 (41%) 1,460 (51%)  
Infectious diseases hospital 14,917 (18%)    452 (16%)  
Centers for diseases control clinic 19,849 (24%)   768 (26%)  
Health care center at township level 10,524 (13%)     144 (5%)  
Village clinic 2,236 (3%)  16 (1%)  
Prison hospital   759 (1%)  42 (1%) <.0001 
CD4 cell counts (cells/ μL)    
0-49 20,604 (27%)  541 (20%)  
50-199 31,658 (41%) 926 (33%)  
200-349 22,805 (29%) 1,180 (43%)  
≥350 2,167 (3%)    107 (4%) <.0001 
Hemoglobin (g/L)    
0-79 3,029 (4%)      80 (3%)  
≥80 71,717(96%) 2,411 (97%) 0.04 
ALT  (U/L)    
≥100 2,852 (4%)    109 (4%)  
0-99 71,413 (96%) 2,466 (96%) 0.31 
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Table A.4 Comparison of Characteristics HIV-infected patients at combination antiretroviral therapy 
initiation between with and without follow-up, the China National Free Antiretroviral Treatment 
Program 2003 - 2010 (continued) 
 
Characteristic With Without  P value 
Number of baseline symptoms     
       ≥4 19,336 (24%)      303 (11%)  
       2-3 17,391 (21%)     408 (14%)  
       1 10,898 (13%)     323 (11%)  
       0 34,302 (42%)  1,862 (64%) <.0001 
Initiation cART regimen    
      NVP+3TC+AZT 28,485 (35%) 1,285 (44%)  
      NVP+3TC+D4T 28,322 (35%)    700 (24%)  
      NVP+DDI+AZT 2,618 (3%)    7 (0%)  
      NVP+DDI+D4T  1,986 (2%)   15 (1%)  
      EFV+3TC+AZT   9,613 (12%)   453 (16%)  
      EFV+3TC+D4T   8,226 (10%)   304 (10%)  
      Other regimens 2,677 (3%) 132 (5%) <.0001 
Year of cART initiation     
      2003-2004 2,182 (3%)   14 (1%)  
      2005-2006   9,880 (15%)   90 (3%)  
      2007-2008 27,149 (40%) 249 (8%)  
      2009-2010 28,521 (42%) 2543 (88%) <.0001 
Note ALT=alanine aminotransferase; cART=Combination Antiretroviral Therapy; NVP= nevirapine; 
3TC=lamivudine; AZT= zidovudine; D4T=stavudine; DDI=didanosine; EFV=efavirenz;  
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Table A.5 Clinical and demographic characteristics associated with attrition among HIV-infected 
patients at combination antiretroviral therapy initiation, the China National Free Antiretroviral 
Treatment Program 2003 - 2010 (including no follow up) 
 
Characteristic Unadjusted HR  
(95% CI) 
*Adjusted HR  
(95% CI) 
Age (years)   
     18-29 1.51 (1.42 -1.60) 1.10 (1.02 - 1.19) 
     30-44 1.28 (1.22 -1.35) 0.94 (0.89 - 1.01) 
     ≥45 1 1 
Gender   
     Male 1.29 (1.24 - 1.34) 1.08 (1.02 - 1.14) 
     Female 1 1 
Marital status   
     Divorced 1.39 (1.30 - 1.50) 1.29 (1.18 - 1.40) 
     Single 1.61 (1.53 - 1.69) 1.25 (1.18 - 1.33) 
     Widowed  0.95 (0.88 - 1.03) 1.10 (1.00 - 1.21) 
     Married  1 1 
HIV exposure   
     Blood transfusion/former plasma donation 0.84 (0.79 - 0.88) 0.74 (0.67 - 0.83) 
     Intravenous drug use 2.18 (2.08 - 2.28) 1.85 (1.75 - 1.96) 
     Homosexual transmission 0.53 (0.46 - 0.62) 0.52 (0.44 - 0.62) 
     Heterosexual transmission 1 1 
Area of residence   
     Eastern region 0.92 (0.86 - 0.97) 1.04 (0.96 - 1.12) 
     Central region 0.62 (0.59 - 0.65) 0.68 (0.62 - 0.75) 
     Western region 1 1 
Health care setting   
     General hospital 2.55 (2.18 - 3.00) 1.20 (0.96 - 1.49) 
     Infectious diseases hospital 2.06 (1.75 - 2.43) 1.09 (0.87 - 1.36) 
     Centers for diseases control clinic 1.66 (1.41 - 1.95) 1.03 (0.83 - 1.28) 
     Health care center at township level 1.77 (1.50 - 2.09) 1.39 (1.12 - 1.72) 
     Prison hospital 5.91 (4.83 - 7.24) 2.35 (1.82 - 3.05) 
     Village clinic 1 1 
CD4 counts (cells/ μL)   
     ≥350 1.57 (1.41 - 1.75) 1.75 (1.54 - 1.99) 
     200-349 1.13 (1.07 - 1.19) 1.07 (1.00 - 1.15) 
     50-199 1.01 (0.96 - 1.07) 1.00 (0.94 - 1.06) 
     0-49 1 1 
Hemoglobin (g/L)   
     0-79 1.22 (1.10 - 1.35) 1.22 (1.08 - 1.37) 
     ≥80 1 1 
ALT (U/L)    
     ≥100 1.27 (1.15 - 1.40)  
     0-99 1  
Number of baseline symptom    
     ≥4 1.07 (1.02 - 1.12) 1.06 (1.00 - 1.13) 
     2-3 0.94 (0.89 - 1.00) 0.97 (0.91 - 1.04) 
     1 0.96 (0.90 - 1.02) 0.96 (0.89 - 1.03) 
     0 1 1 
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Table A.5 Clinical and demographic characteristics associated with attrition among HIV-infected 
patients at combination antiretroviral therapy initiation, the China National Free Antiretroviral 
Treatment Program 2003 - 2010 (including no follow up) (continued) 
 
Characteristic Unadjusted HR  
(95% CI) 
*Adjusted HR 
 (95% CI) 
Initiation cART regimen   
      NVP+3TC+AZT 0.90 (0.84 - 0.97) 0.95 (0.88 - 1.03) 
      NVP+3TC+D4T 0.92 (0.85 - 0.98) 0.86 (0.79 - 0.93) 
      NVP+DDI+AZT 1.20 (1.08 - 1.34) 1.58 (1.34 - 1.86) 
      NVP+DDI+D4T 1.18 (1.06 - 1.32) 0.92 (0.77 - 1.10) 
      EFV+3TC+AZT 1 1 
      EFV+3TC+D4T 0.89 (0.81 - 0.98) 0.83 (0.75 - 0.92) 
      Other regimens 1.32 (1.18 - 1.47) 1.29 (1.13 - 1.49) 
Year of cART initiation    
     2003-2004 2.25 (2.06 - 2.46) 3.23 (2.79 - 3.74) 
     2005-2006 1.71 (1.61 - 1.82) 1.71 (1.58 - 1.84) 
     2007-2008 1.31 (1.24 - 1.38) 1.25 (1.18 - 1.33) 
     2009-2010 1 1 
*Adjusted hazard ratios are based on one model including all characteristics listed in column except 
ALT. Note: HR = hazard ratio; 95% CI = 95% Confidence Interval; ALT=alanine aminotransferase; 
cART=Combination Antiretroviral Therapy; NVP= nevirapine; 3TC=lamivudine; AZT= zidovudine; 
D4T=stavudine; DDI=didanosine; EFV=efavirenz. 
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Appendix B  
Additional figures 
Figure A.1 Cumulative probability of attrition among HIV-infected patients who initiated 
combination antiretroviral therapy in the China National Free Antiretroviral Treatment Program, 
2003-2010 by age group 
 
  
 
No. at risk       
18-29 11509 8309 4682 2440 1081 399 
30-44 38200 27947 16550 9158 4338 1815 
>=45 18023 12808 7210 3805 1828 792 
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Figure A.2 Cumulative probability of attrition among HIV-infected patients who initiated 
combination antiretroviral therapy in the China National Free Antiretroviral Treatment Program, 
2003-2010 by gender group  
 
 
  
 
No. at risk       
Female 24930 18829 11443 6459 3102 1336 
Male 42798 30231 16997 8943 4145 1670 
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 Figure A.3 Cumulative probability of attrition among HIV-infected patients who initiated 
combination antiretroviral therapy in the China National Free Antiretroviral Treatment Program, 
2003-2010  by marriage status group  
 
 
  
 
No. at risk       
Single 10875 7547 3970 1907 833 290 
Divorced 4864 3296 1708 817 347 127 
Married 46434 34143 20355 11349 5425 2312 
Widowed 5399 3987 2384 1320 639 276 
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Figure A.4 Cumulative probability of attrition among HIV-infected patients who initiated 
combination antiretroviral therapy in the China National Free Antiretroviral Treatment Program, 
2003-2010 by alanine aminotransferase group 
 
 
  
 
No. at risk       
>=100 2421 1682 984 513 232                          86 
0-99 58875 43048 24636 13012 5884                      2247 
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Figure A.5 Cumulative probability of attrition among HIV-infected patients who initiated 
combination antiretroviral therapy in the China National Free Antiretroviral Treatment Program, 
2003-2010 by hemoglobin group  
 
 
  
 
No. at risk       
0-79 2612 1524 934 553 273 91 
≥80 59269 43626 25113 13329 6155 2448 
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Figure A.6 Cumulative probability of attrition among HIV-infected patients who initiated 
combination antiretroviral therapy in the China National Free Antiretroviral Treatment Program, 
2003-2010 by region  
 
 
  
 
No. at risk       
Western area 38095 27111 15043 7304 3065 970 
Eastern area 8359 5856 3077 1667 828 373 
Central area 21278 16097 10322 6432 3354 1663 
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Figure A.7 Cumulative probability of attrition among HIV-infected patients who initiated 
combination antiretroviral therapy in the China National Free Antiretroviral Treatment Program, 
2003-2010 by health care setting.  
 
Note:  CDC= Centers for diseases control clinic. 
  
 
No. at risk       
Prison hospital 646 445 172 47 14 4 
General hospital 26801 18942 10402 4957 2050 725 
Infectious diseases hospital 12321 8956 5145 2830 1338 472 
CDC 16019 11479 6826 4094 2375 1238 
Health center at township  9496 7252 4607 2793 1246 562 
Village clinic 2000 1653 1099 598 206 3 
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Figure A.8 Distribution of follow up time among 64,836 HIV-infected patients at combination 
antiretroviral therapy initiation, the China National Free Antiretroviral Treatment Program 2003 - 
2009  
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